Wound dressing and method of treatment

Information

  • Patent Grant
  • 11596552
  • Patent Number
    11,596,552
  • Date Filed
    Monday, April 6, 2020
    4 years ago
  • Date Issued
    Tuesday, March 7, 2023
    a year ago
Abstract
Embodiments disclosed herein are directed to negative pressure treatment systems and wound dressing systems, apparatuses, and methods that may be used for the treatment of wounds. In particular, some embodiments are directed to improved wound dressings comprising a number of viewing portals that facilitate observation of wound tissue or healthy skin underlying the wound dressing. Some embodiments of the viewing portals are provided by forming through holes in internal dressing layers including absorbent material and transmission material, optionally by providing a plug material within the through holes, and by providing translucent or transparent cover layer and tissue contact layer materials.
Description
FIELD OF THE INVENTION

Embodiments described herein relate to apparatuses, systems, and methods the treatment of wounds, for example using dressings in combination with negative pressure wound therapy.


SUMMARY OF THE INVENTION

Certain embodiments disclosed herein relate to improved wound dressings that exhibit enhanced visibility for underlying patient tissue. Such dressings may have advantages over prior art dressings, through which assessment of the condition of a tissue site underlying the dressing is difficult or not possible. Also disclosed are improved methods of use and systems for use of the same, preferably in conjunction with negative pressure wound therapy.


In one embodiment, an apparatus for negative pressure wound therapy comprises:

    • a wound dressing comprising:
    • a material layer comprising one or more through holes extending vertically through a thickness of the material layer; and
    • a transparent or translucent cover layer positioned above the absorbent layer, the cover layer configured to form a negative pressure chamber underneath the cover layer; and
    • a port configured to communicate negative pressure to the negative pressure chamber;
    • wherein the one or more through holes in the material layer permit viewing of tissue beneath the wound dressing through the wound cover when the wound dressing is applied to a patient.


In some embodiments, the wound dressing comprises one or more lower layers beneath the material layer, wherein the through holes in the material layer permit viewing of tissue beneath the wound dressing through the wound cover and through the one or more lower layers when the wound dressing is applied to a patient. The one or more lower layers may comprise one or more transparent or translucent layers. The one or more lower layers may comprise a lower layer comprising one or more through holes extending vertically through a thickness of the lower layer. At least some of the vertically extending through holes in the lower layer may be positioned underneath at least some of the vertically extending through holes in the material layer. The vertically extending through holes in the lower layer may be smaller than the vertically extending through holes in the material layer. The one or more lower layers may comprise a tissue contact layer and a transmission layer over the tissue contact layer. The material layer may be an absorbent layer.


Some or all of the through holes in the material layer and in any lower layer may be circular in shape. Some or all of the through holes in the material layer and in any lower layer may be hexagonal in shape. Some or all of the through holes in the material layer and in any lower layer may be diamond-shaped. In some embodiments the apparatus may further comprise a filter in or below the port to retain wound exudate underneath the cover layer. The apparatus may further comprise a fluid collection canister for storage of fluids transported from the wound dressing. The port may be attached over a hole in the cover layer. The apparatus may further comprise a conduit connected to the port configured to supply negative pressure to the wound dressing. The apparatus may further comprise a source of negative pressure configured to supply negative pressure to the wound dressing.


In some embodiments, the wound dressing may further comprise a plug material positioned within at least some of the one or more through holes. The plug material may prevent or minimize suction blisters forming in the tissue underneath the at least some of the one or more through holes. The plug material may comprise a soft, transparent material. The plug material may comprise a soft, transparent, and hydrophobic material. The plug material may comprise silicone. In some embodiments, the one or more through holes can be configured to prevent or minimize suction blisters to the tissue by having a limited diameter. The limited diameter can be less than or equal to approximately 10 mm.


In another embodiment, an apparatus for negative pressure wound comprises:

    • a wound dressing comprising:
    • a transmission layer comprising one or more through holes extending vertically through a thickness of the transmission layer;
    • an absorbent layer comprising one or more through holes extending vertically through a thickness of the absorbent layer; and
    • a transparent or translucent cover layer positioned above the absorbent layer, the cover layer configured to form a negative pressure chamber underneath the cover layer; and
    • a port configured to communicate negative to pressure to the negative pressure chamber;
    • wherein the one or more through holes in the transmission layer are positioned at least partially below the one or more through holes in the absorbent layer to permit viewing of tissue beneath the wound dressing through the wound cover when the wound dressing is applied to a patient.


In some embodiments, the transmission layer comprises a plurality of horizontally spaced apart through holes extending vertically through the thicknesss of the transmission layer, and the absorbent layer comprises a plurality of horizontally spaced apart through holes extending vertically through the thickness of the absorbent layer. The plurality of horizontally spaced apart through holes in the transmission layer may be distributed in a regularly spaced pattern across the transmission layer, and the plurality of horizontally spaced apart through holes in the absorbent layer may be distributed in a regularly spaced pattern across the absorbent layer. The plurality of horizontally spaced apart through holes in the transmission layer may be spaced apart by 10 mm (or about 10 mm) or less, and the plurality of horizontally spaced apart through holes in the absorbent layer may be spaced apart by 10 mm (or about 10 mm) or less. The plurality of horizontally spaced apart through holes in the transmission layer may be formed in a first pattern across an area of the transmission layer, and the plurality of horizontally spaced apart through holes in the absorbent layer may be formed in a second pattern across an area of the transmission layer.


In some embodiments, at least one through hole extending vertically through the thickness of the transmission layer is located below each through hole extending vertically through the thickness of the absorbent layer. Two or more through holes extending vertically through the thickness of the transmission layer may be located below each through hole extending vertically through the thickness of the absorbent layer. The through hole(s) extending vertically through the thickness of the absorbent layer may be larger in dimension than through hole(s) extending vertically through the thickness of the transmission layer. Some or all of the through holes in the transmission layer and/or the absorbent layer may be circular in shape. Some or all of the through holes in the transmission layer and/or the absorbent layer may be hexagonal in shape. Some or all of the through holes in the transmission layer and/or the absorbent layer may be diamond-shaped. T


In some embodiments, the one or more through holes in the absorbent layer can have a diameter of 10 mm (or about 10 mm) or less. The one or more through holes in the transmission layer can have a diameter of 5 mm (or about 5 mm) or less. The one or more through holes in the transmission layer can have a diameter of 1 mm (or about 1 mm) or less.


In some embodiments, the apparatus may further comprise a tissue contact layer positioned below the transmission layer. The cover layer may be configured to seal around a perimeter thereof to the tissue contact layer. The tissue contact may be is configured to seal directly to a patient's tissue. The transmission layer may comprise 3D fabric. The absorbent layer may comprise a non-woven material comprising a plurality of superabsorbing particles. In some embodiments, the apparatus may further comprise a fluid collection canister for storage of fluids transported from the wound dressing.


In some embodiments, the apparatus may further comprise a filter in or below the port to retain wound exudate underneath the cover layer. The port may be attached over a hole in the cover layer. In some embodiments, the apparatus may further comprise a conduit connected to the port configured to supply negative pressure to the wound dressing. In some embodiments, the apparatus may further comprise a source of negative pressure configured to supply negative pressure to the wound dressing.


In some embodiments, the apparatus may further comprise a plug material positioned within at least some of the one or more through holes. The plug material may prevent or minimize suction blisters forming in the tissue underneath the at least some of the one or more through holes. The plug material may comprise a soft, transparent material. The plug material may comprise a soft, transparent, and hydrophobic material. The plug material may comprise silicone.


In some embodiments, the one or more through holes can be configured to prevent or minimize suction blisters to the tissue by having a limited diameter. The limited diameter can be less than or equal to approximately 10 mm.





BRIEF DESCRIPTION OF THE DRAWINGS

The disclosed aspects will hereinafter be described in conjunction with the appended drawings, provided to illustrate and not to limit the disclosed aspects, wherein like designations denote like elements.



FIG. 1 illustrates an embodiment of a wound treatment system;



FIGS. 2A-E illustrate the use and application of an embodiment of a wound treatment system onto various wounds;



FIGS. 3A-3C illustrate an embodiment of a wound dressing configured for enhanced tissue visibility;



FIGS. 4A-4C illustrate another embodiment of a wound dressing configured for enhanced tissue visibility;



FIGS. 5A-5C illustrate another embodiment of a wound dressing configured for enhanced tissue visibility;



FIGS. 6A-6C illustrate various embodiments of a wound dressing configured for enhanced tissue visibility;



FIG. 7 illustrates another embodiment of a wound dressing configured for enhanced tissue visibility;



FIGS. 8A and 8B illustrate one embodiment of spacer layer material;



FIGS. 9A and 9B illustrate one embodiment of acquisition distribution layer material;



FIGS. 10A and 10B illustrate one embodiment of absorbent layer material; and



FIG. 11 illustrates one embodiment of an adhesive spread on cover layer material.



FIGS. 12A-12E are photographic representations of various embodiments of a wound dressing configured for enhanced tissue visibility through plug material.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Embodiments disclosed herein relate to apparatuses and methods of treating a wound with reduced pressure, including pump and wound dressing components and apparatuses. The apparatuses and components comprising the wound overlay and packing materials, if any, are sometimes collectively referred to herein as dressings.


It will be appreciated that throughout this specification reference is made to a wound. It is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured or where trauma causes a contusion, or any other superficial or other conditions or imperfections on the skin of a patient or otherwise that benefit from reduced pressure treatment. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, abdominal wounds or other large or incisional wounds, either as a result of surgery, trauma, sterniotomies, fasciotomies, or other conditions, dehisced wounds, acute wounds, chronic wounds, subacute and dehisced wounds, traumatic wounds, flaps and skin grafts, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like. Some embodiments of the dressings described herein may be used over a tissue site susceptible to form a wound or likely to form a wound, for example a tissue site over a bony prominence susceptible to forming a pressure ulcer.


It will be understood that embodiments of the present disclosure are generally applicable to use in topical negative pressure (“TNP”) therapy systems. Briefly, negative pressure wound therapy assists in the closure and healing of many forms of “hard to heal” wounds by reducing tissue oedema; encouraging blood flow and granular tissue formation; removing excess exudate and may reduce bacterial load (and thus infection risk). In addition, the therapy allows for less disturbance of a wound leading to more rapid healing. TNP therapy systems may also assist on the healing of surgically closed wounds by removing fluid and by helping to stabilize the tissue in the apposed position of closure. A further beneficial use of TNP therapy can be found in grafts and flaps where removal of excess fluid is important and close proximity of the graft to tissue is required in order to ensure tissue viability.


As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels that are below standard atmospheric pressure, which corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects absolute pressure that is X mmHg below 760 mmHg or, in other words, an absolute pressure of (760−X) mmHg. In addition, negative pressure that is “less” or “smaller” than X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than −60 mmHg).


The negative pressure range for some embodiments of the present disclosure can be approximately −80 mmHg, or between about −20 mmHg and −200 mmHg. Note that these pressures are relative to normal ambient atmospheric pressure. Thus, −200 mmHg would be about 560 mmHg in practical terms. In some embodiments, the pressure range can be between about −40 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also in other embodiments a pressure range of below −75 mmHg can be used. Alternatively, a pressure range of over approximately −100 mmHg, or even 150 mmHg, can be supplied by the negative pressure apparatus. In some embodiments of wound closure devices described here, increased wound contraction can lead to increased tissue expansion in the surrounding wound tissue. This effect may be increased by varying the force applied to the tissue, for example by varying the negative pressure applied to the wound over time, possibly in conjunction with increased tensile forces applied to the wound via embodiments of the wound closure devices. In some embodiments, negative pressure may be varied over time for example using a sinusoidal wave, square wave, and/or in synchronization with one or more patient physiological indices (e.g., heartbeat).


As used herein, the term “horizontal,” when referring to a wound, indicates a direction or plane generally parallel to the skin surrounding the wound. The term “vertical,” when referring to a wound, generally refers to a direction extending perpendicular to the horizontal plane. The terms “horizontal” and “vertical” may also be used to describe the components of the wound treatment system, such as layers of the wound dressing. When describing these components, these terms should not be construed to require that the structures or devices necessarily be placed into a wound in a certain orientation, though in certain embodiments, it may be preferable to do so.


I. Example Systems and Use



FIG. 1 illustrates an embodiment of a TNP wound treatment system 100 comprising a wound dressing 110 in combination with a pump 150. The wound dressing 110 can be any wound dressing embodiment disclosed herein including without limitation dressing embodiment or have any combination of features of any number of wound dressing embodiments disclosed herein. Here, the dressing 110 may be placed over a wound as described previously, and a conduit 130 may then be connected to the port 120, although in some embodiments the dressing 101 may be provided with at least a portion of the conduit 130 preattached to the port 120. Alternatively, in some embodiments the dressing 110 can be placed over a tissue site likely to form a wound, such as a pressure site likely to form a pressure ulcer. Preferably, the dressing 110 is provided as a single article with all wound dressing elements (including the port 120) pre-attached and integrated into a single unit. The wound dressing 110 may then be connected, via the conduit 130, to a source of negative pressure such as the pump 150. The pump 150 can be miniaturized and portable, although larger conventional pumps may also be used with the dressing 110. In some embodiments, the pump 150 may be attached or mounted onto or adjacent the dressing 110. A connector 140 may also be provided so as to permit the conduit 130 leading to the wound dressing 110 to be disconnected from the pump, which may be useful for example during dressing changes. Embodiments of the dressing of FIG. 1 are further described with respect to FIGS. 3A-11, which also provide additional details on the specific internal components of the dressing embodiment depicted in FIG. 1.


In some embodiments, fluid may be transported from the dressing 110 and stored in a fluid collection canister (not shown). Some embodiments, may call for fluid to be retained within the dressing such as within an absorbent material. The absorbent material may further comprise a superabsorbent polymer or a more conventional absorbent material such as cellulose.



FIGS. 2A-D illustrate the use of an embodiment of a TNP wound treatment system being used to treat a wound site on a patient. FIG. 2A shows a wound site 200 being cleaned and prepared for treatment. Here, the healthy skin surrounding the wound site 200 is preferably cleaned and excess hair removed or shaved. The wound site 200 may also be irrigated with sterile saline solution if necessary. Optionally, a skin protectant may be applied to the skin surrounding the wound site 200. If necessary, a wound packing material, such as foam or gauze, may be placed in the wound site 200. This may be preferable if the wound site 200 is a deeper wound. In embodiments, the wound may be any type of wound described herein this section or elsewhere in the specification.



FIG. 2B illustrates an incisional wound site 202 that may be irrigated and prepared as the wound site 200 described in relation to FIG. 2A. Typical incisional wounds are created by a scalpel or other means during surgery to allow a clinician access to the underlying tissues and organs. The incisional wound 202 may be closed, whereby the wound has been closed by sutures 204 or other means such as an adhesive, or the incisional wound may be open, wherein the wound has not yet been closed. As described above, throughout this specification reference is made to a wound and such a wound may be created by a variety of means including via incisional means. Thus, it will be understood by one skilled in the art, when the term “wound” is used in describing embodiments herein this section and elsewhere in the specification, the term “wound” encompasses incisional wounds such as those described in FIG. 2B. Although not illustrated, the term “wound” also encompasses potential wound sites, such as bony prominences that may form a pressure ulcer.


After the skin surrounding the wound site 200 is dry, and with reference now to FIG. 2C, the wound dressing 110 may be positioned and placed over the wound site 200 or 202. Preferably, the wound dressing 110 is placed over and/or in contact with the wound site 200. In some embodiments, an adhesive layer is provided on the lower surface of the dressing 110, which may in some cases be protected by an optional release layer to be removed prior to placement of the wound dressing 110 over the wound site 200. Preferably, the dressing 110 is positioned such that the port 120 is in a raised position with respect to the remainder of the dressing 110 so as to avoid fluid pooling around the port. In some embodiments, the dressing 110 is positioned so that the port 120 is not directly overlying the wound, and is level with or at a higher point than the wound. To help ensure adequate sealing for negative pressure wound therapy, the edges of the dressing 110 are preferably smoothed over to avoid creases or folds.


With reference now to FIG. 2D, the dressing 110 is connected to the pump 150. The pump 150 is configured to apply negative pressure to the wound site via the dressing 110, and typically through a conduit. In some embodiments, and as described above in FIG. 1, a connector may be used to join the conduit from the dressing 110 to the pump 150. Upon the application of negative pressure with the pump 150, the dressing 110 may, in some embodiments, partially collapse and present a wrinkled appearance as a result of the evacuation of some or all of the air underneath the dressing 110. In some embodiments, the pump 150 may be configured to detect if any leaks are present in the dressing 110, such as at the interface between the dressing 110 and the skin surrounding the wound site 200. Should a leak be found, such leak is preferably remedied prior to continuing treatment.


Turning to FIG. 2E, additional fixation strips 210 may also be attached around the edges of the dressing 110. Such fixation strips 210 may be advantageous in some situations so as to provide additional sealing against the skin of the patient surrounding the wound site 200. For example, the fixation strips 210 may provide additional sealing for when a patient is more mobile. In some cases, the fixation strips 210 may be used prior to activation of the pump 150, particularly if the dressing 110 is placed over a difficult to reach or contoured area.


Treatment of the wound site 200 preferably continues until the wound has reached a desired level of healing. In some embodiments, it may be desirable to replace the dressing 110 after a certain time period has elapsed, or if the dressing is full of wound fluids. During such changes, the pump 150 may be kept, with just the dressing 110 being changed.


II. Example Dressings



FIGS. 3A-C illustrate various views of a viewing portal wound dressing 300 that can be used in a similar system to FIG. 1 to provide visibility of underlying tissue according to an embodiment of the disclosure. In some circumstances, it can be beneficial for a clinician to be able to visually assess the quality of the tissue underlying the dressing 300. For example, a clinician can assess the progress of healing of wound tissue underlying the dressing 300 in some examples. Viewing portals 330 in the dressing 300 permit viewing of tissue beneath the wound dressing through the wound cover when the wound dressing is applied to a patient, for example allowing a clinician to view the tissue underlying the dressing to determine whether the tissue is a wound site, healthy tissue, or an infection, to name a few. In other examples, the dressing 300 can be applied as a prophylactic measure to healthy or relatively healthy skin in an area that may form a wound and the clinician may wish to monitor changes in the underlying tissue to determine whether a wound is forming. By monitoring changes in the color of the underlying tissue or for signs of the dermis breaking down, a clinician can determine whether further treatment is needed, such as debridement. For instance, the dressing 300 may be applied to a bony prominence possibly prone to forming a pressure ulcer. The dressing 300 can provide cushioning to protect the bony prominence, and the blood perfusion resulting from negative pressure applied through the dressing 300 can provide therapeutic benefits including preventing, delaying, or mitigating formation of pressure ulcers. The viewing portals 330 in the dressing 300 can allow a clinician to determine whether a wound has formed in the underlying tissue and/or determine an approximate area of an ulcer. In other examples, the dressing 300 can be applied as a prophylactic measure to reddened or bruised tissue, to tissue on pressure points such as the shoulder or buttocks of bedridden patients, or the like. The material layers of the dressing 300 can serve to transmit negative pressure to the tissue site and also absorb any initial exudate from formation of a wound. These are just a few circumstances in which a clinician may wish to monitor changes in tissue underlying a dressing 300. The clinician can use viewing portals 330 through the internal layers of the dressing to monitor tissue characteristics and changes, as discussed in more detail below.



FIG. 3A illustrates a top view of the wound dressing 300, FIG. 3B illustrates a schematic cross-sectional view of the wound dressing 300, and FIG. 3C illustrates an exploded view of various layers of the wound dressing 300. The wound dressing 300 can be located over a wound site or potentially wound-forming tissue site to be treated. The dressing 300 may be placed so as to form a sealed cavity over the wound site. In some embodiments, the dressing 300 comprises a cover layer 345 attached to an optional tissue contact layer 350, both of which are described in greater detail below. These two layers 345, 350 are preferably joined or sealed together around a perimeter 305 so as to define an interior space or chamber. The cover layer 345 can be configured to form a negative pressure chamber underneath the cover layer. The interior space or chamber may comprise additional structures that may be adapted to distribute or transmit negative pressure, store wound exudate and other fluids removed from the wound, and other functions which will be explained in greater detail below. Examples of such structures, described below, include a transmission layer 310 and/or an absorbent layer 320.


The various layers used to form the wound dressing 300 or other wound dressings described in this specification may have any of a number of perimeter shapes when viewed from above, as in FIG. 3A. For example, the layers may have a rectangular, square, elongated, elliptical, circular or other shapes. In some embodiments, each of the layers has the same or similar shape, though they may be of different sizes (as shown in FIG. 3C). FIG. 3A illustrates layers that have a rectangular shape with a length and a width extending within a horizontal plane. FIG. 3B illustrates that each of the layers may have a vertical thickness perpendicular to the horizontal dimensions of the layers.


As illustrated in FIGS. 3A-C, a lower surface of the wound dressing 300 may be provided with an optional tissue contact layer 350. The tissue contact layer 350 can for example be a polyurethane layer or polyethylene layer or other flexible layer which is perforated, for example via a hot pin process, laser ablation process, ultrasound process or in some other way or otherwise made permeable to liquid and gas. The tissue contact layer 350 has a lower surface and an upper surface. As shown in FIG. 3B, perforations 360 may be provided in the tissue contact layer 350, preferably comprising through holes in the tissue contact layer 350 which enable fluid to flow through the layer 350. The tissue contact layer 350 can help prevent tissue ingrowth into the other material of the wound dressing. Preferably, the perforations 360 are small enough to meet this requirement while still allowing fluid to flow therethrough. For example, perforations 360 formed as slits or holes having a size ranging from approximately 0.025 mm to approximately 1.2 mm, for example 1 mm (or about 1 mm) are considered small enough to help prevent tissue ingrowth into the wound dressing while allowing wound exudate to flow into the dressing. In some configurations, the tissue contact layer 350 may help maintain the integrity of the entire dressing 300 while also creating an air tight seal around the internal layers in order to maintain negative pressure at the wound.


Some embodiments of the tissue contact layer 350 may also act as a carrier for an optional lower and/or upper adhesive layer (not shown). For example, a lower pressure sensitive adhesive may be provided on the lower surface of the tissue contact layer 350 whilst an upper pressure sensitive adhesive layer may be provided on the upper surface of the tissue contact layer 350. In some embodiments a pressure sensitive adhesive, which may be a silicone, hot melt, hydrocolloid or acrylic based adhesive or other such adhesives, may be formed on both sides or optionally on a selected one side of the tissue contact layer. In certain embodiments, the upper adhesive layer may comprise an acrylic pressure sensitive adhesive, and the lower adhesive layer may comprise a silicone pressure sensitive adhesive. In other embodiments the tissue contact layer 350 may not be provided with adhesive. In some embodiments, the tissue contact layer 350 may be transparent or translucent. The film layer of the tissue contact layer 350 may define a perimeter with a rectangular or a square shape. A release layer (not illustrated) may be removably attached to the underside of the tissue contact layer 350, for example covering the lower adhesive layer, and may be peeled off using flaps. Some embodiments of the release layer may have a plurality of flaps extending along the length of the layer. In some embodiments, the tissue contact layer 350 may comprise perforated polyurethane film. The lower surface of the film may be provided with a silicone pressure sensitive adhesive and the upper surface may be provided with an acrylic pressure sensitive adhesive, which may help the dressing maintain its integrity. In some embodiments, a polyurethane film layer may be provided with an adhesive layer on both its upper surface and lower surface, and all three layers (the upper adhesive layer, the film layer, and the lower adhesive layer) may be perforated together.


An optional layer of porous material can be located above the tissue contact layer 350. This porous layer, or transmission layer 320, allows transmission of fluid including liquid and gas away from a wound site into upper layer(s) of the wound dressing 300. In particular, the transmission layer 320 preferably ensures that an open air channel can be maintained to communicate negative pressure over the wound area even when the overlying absorbent layer 310 has absorbed substantial amounts of exudates. The transmission layer 320 should preferably remain open under the typical pressures that will be applied during negative pressure wound therapy as described above, so that the whole wound site sees an equalized negative pressure.


Some embodiments of the transmission layer 320 may be formed of a material having a three dimensional structure. For example, a knitted or woven spacer fabric (for example Baltex 7970 weft knitted polyester) or a non-woven fabric can be used. In some embodiments, the transmission layer 320 can have a 3D polyester spacer fabric layer. This layer can have a top layer which is a 84/144 textured polyester, and a bottom layer which can be a 100 denier flat polyester and a third layer formed sandwiched between these two layers which is a region defined by a knitted polyester viscose, cellulose or the like monofilament fiber. In use, this differential between filament counts in the spaced apart layers tends to draw liquid away from the wound bed and into a central region of the dressing 300 where the absorbent layer 310 helps lock the liquid away or itself wicks the liquid onwards towards the cover layer 345 where it can be transpired. Other materials can be utilized, and examples of such materials are described in U.S. Patent Pub. No. 2011/0282309, which are hereby incorporated by reference and made part of this disclosure.


Some embodiments of the transmission layer 320 may additionally or alternatively comprise a wicking or acquisition distribution material (ADL) to horizontally wick fluid such as wound exudate as it is absorbed upward through the layers of the dressing 300. Lateral wicking of fluid may allow maximum distribution of the fluid through the absorbent layer 330 and may enable the absorbent layer 310 to reach its full holding capacity. This may advantageously increase moisture vapor permeation and efficient delivery of negative pressure to the wound site. Some embodiments of the transmission layer 320 may comprise viscose, polyester, polypropylene, cellulose, or a combination of some or all of these, and the material may be needle-punched. Some embodiments of the transmission layer 320 may comprise polyethylene in the range of 40-150 grams per square meter (gsm).


Further details of example suitable materials for a transmission layer 320 are discussed below with respect to FIGS. 8A-9B.


A layer 310 of absorbent material may be provided above the transmission layer 320. The absorbent material, which can comprise a foam or non-woven natural or synthetic material, and which may optionally comprise a super-absorbent material, forms a reservoir for fluid, particularly liquid, removed from the wound site. In some embodiments, the absorbent layer 310 may also aid in drawing fluids towards the cover layer 345. The absorbent layer 310 can be manufactured from ALLEVYN™ foam, Freudenberg 114-224-4 and/or Chem-Posite™ 11C-450, or any other suitable material. Some embodiments of the absorbent layer can be constructed from hydrophilic foam, for example a hydrophilic polyurethane prepolymer such as HYPOL™. In some embodiments, the absorbent layer 310 can be a layer of non-woven cellulose fibers having super-absorbent material in the form of dry particles dispersed throughout. Use of the cellulose fibers introduces fast wicking elements which help quickly and evenly distribute liquid taken up by the dressing. The juxtaposition of multiple strand-like fibers leads to strong capillary action in the fibrous pad which helps distribute liquid.


For example, some embodiments of the absorbent layer 310 may comprise a layered construction of an upper layer of non-woven cellulose fibers, superabsorbent particles (SAP), and a lower layer of cellulose fibers with 40-80% SAP. In some embodiments, the absorbent layer 310 may be an air-laid material. Heat fusible fibers can optionally be used to assist in holding the structure of the pad together. Some embodiments may combine cellulose fibers and air-laid materials, and may further comprise up to 60% SAP. Some embodiments may comprise 60% SAP and 40% cellulose. Other embodiments of the absorbent layer may comprise between 60% and 90% (or between about 60% and about 90%) cellulose matrix and between 10% and 40% (or between about 10% and about 40%) superabsorbent particles. For example, the absorbent layer 310 may have about 20% superabsorbent material and about 80% cellulose fibers. It will be appreciated that rather than using super-absorbing particles or in addition to such use, super-absorbing fibers can be utilized according to some embodiments of the present invention. An example of a suitable material is the Product Chem-Posite™ 11 C available from Emerging Technologies Inc (ETi) in the USA.


Super-absorber particles/fibers can be, for example, sodium polyacrylate or carbomethoxycellulose materials or the like or any material capable of absorbing many times its own weight in liquid. In some embodiments, the material can absorb more than five times its own weight of 0.9% W/W saline, etc. In some embodiments, the material can absorb more than 15 times its own weight of 0.9% W/W saline, etc. In some embodiments, the material is capable of absorbing more than 20 times its own weight of 0.9% W/W saline, etc. Preferably, the material is capable of absorbing more than 30 times its own weight of 0.9% W/W saline, etc. The absorbent layer 310 can have one or more through holes 355 located so as to underlie the suction port 335.


Further details of example suitable absorbent materials are discussed below with respect to FIGS. 10A-10B.


As illustrated in FIGS. 3A and 3C, the absorbent layer 310 may include a number of through holes 315 and the transmission layer 320 can include an additional number of through holes 325. In some embodiments, the through holes 315 in the absorbent layer 310 and the through holes 325 in the transmission layer 320 can be aligned to form viewing portals 330 through the internal layers of the dressing 300. Due to the transparency or translucency of the cover layer 345 and tissue contact layer 350, the viewing portals 330 can permit viewing of tissue beneath the wound dressing through the wound cover when the wound dressing is applied to a patient, for example for assessment of characteristics of and changes in tissue underlying the dressing 300. In some embodiments, the pattern of the viewing portals 330 can aid a clinician in assessing the progress of healing of a wound underlying the dressing 300 by identifying locations at which new healthy skin has formed. In other embodiments, the pattern of the viewing portals 330 can aid a clinician in assessing the formation and area of a wound forming under the dressing 300, such as a diabetic ulcer or a pressure ulcer. In some embodiments, through holes 325 in the transmission layer 320 may be approximately 2 mm in diameter and may be aligned with smaller holes or perforations in the tissue contact layer 350. As discussed above, perforations 360 may be formed in the tissue contact layer, and may be approximately 1 mm in diameter in some embodiments.


In some embodiments, some or all of through holes 315, 325 may comprise (that is, be plugged or filled using) a plug material, for example a soft, transparent and optionally hydrophobic material (e.g. silicone). Positioning such plug material within through holes 315, 325 can beneficially reduce the risk of underlying skin or tissue being sucked into voids in the dressing when the dressing is under negative pressure. Accordingly, in some examples the through holes 325 that are closest to the wound site may be filled with plug material while the through holes 315 further from the wound site may not be filled. Alternatively, the through holes 315 further from the wound site may be filled, and the through holes 325 closer to the wound site may not be filled with plug material. The plug material can additionally provide the benefit of preventing lateral swelling of super absorbent particles in the absorbent layer 310, which can cause the particles to spill out of the absorbent layer 310 material at the cut edges, thereby filling (at least partially) the through holes 315, 325. Accordingly, in some examples at least the through holes 315 in the absorbent layer may be filled with plug material. In one embodiment, an absorbent layer and an underlying transmission layer can have through holes that are aligned or substantially aligned, such that there is some visibility to the underlying patient tissue. The through holes in the absorbent layer can be filled with plug material, while the through holes in the transmission layer positioned between the absorbent layer and the wound site are not filled with plug material. Such a configuration can provide for better transmission of negative pressure to tissue underlying the plugged through holes compared to embodiments which provide plug material in a material layer positioned adjacent to the wound site.


The transparency of the plug material provides visibility through to the wound bed. As a result of the hydrophobic nature of some embodiments of the plug material, the viewing portals 330 will remain transparent throughout wear time as colored wound exudate and other substances should not be drawn into the plug material because it is hydrophobic. Some examples of the plug material are not absorbent so as to not fill with exudate. In some embodiments, larger through holes can be provided in dressing embodiments using the plug material within through holes compared to dressing embodiments without plug material, for example due to removal of size constraints for preventing patient tissue from being drawn into the holes. In some embodiments, when plugs are provided in through holes 315 of the absorbent layer 310 and optionally in the through holes 325 of the transmission layer 310, the through holes 325 of the transmission layer 320 may be the same shape and dimension as the through holes 315. In other embodiments, when plugs are provided in through holes 315 of the absorbent layer 310, no transmission layer 310 is provided.


The through holes 315 in the absorbent layer 310 may form a repeating pattern across the area of the absorbent layer 310 with the exception of the area of the absorbent layer 310 including the through hole 355 for the port 335. Here the repeating pattern is illustrated as a grid or array of through holes 315 though in other embodiments other patterns can be used. In some embodiments, the through holes 315 in the absorbent layer 310 and the through holes 325 in the transmission layer 320 may be spaced apart by 10 mm (or about 10 mm) or less. The through hole 355 underlying the port 335 is illustrated as being separate from the repeating pattern of through holes 315 and larger than the through holes 315, however in some embodiments the repeating pattern of through holes 315 can continue across the entire area (or substantially all of the area) of the absorbent layer 310 and the port can be placed over a selected one of the through holes in the array, or over a selected group of adjacent through holes in the array. In the illustrated embodiment, the transmission layer 320 has no through holes underlying the through hole 355 in the absorbent layer 310 over which the port 335 is applied. However, in other embodiments the pattern of through holes 325 in the transmission layer 320 may continue under the through hole 355 in the absorbent layer 310.


The through holes 315, 325 can be cut or formed in some embodiments by punching, die cutting, or laser cutting the sheet materials used to form the absorbent layer 310 and the transmission layer 320. However, the creation of apertures, for example by hole-punching, has the disadvantages of resulting in the generation of waste and also the mechanical weakening of the material. By forming through slits in a material, these slits being capable of expanding to form apertures on extension of the material, increased visibility of the wound can be achieved without significant material waste. In this manner, it is also possible to achieve extension of the slit to form a circular hole without mechanically weakening the material. Examples of such lattice cutting techniques are disclosed in International Patent Publication No. PCT/US2007/079529, filed Sep. 26, 2007, titled “LATTICE DRESSING,” the entirety of which is hereby incorporated by reference. In some embodiments, for example embodiments in which the through holes 315 in the absorbent layer 310 and the through holes 325 transmission layer 325 are different sizes or are arranged in different patterns, the absorbent layer 310 and transmission layer 325 can be cut separately from one another by any of the previously described hole-forming processes. In some embodiments, the absorbent layer 310 and transmission layer 320 can be stacked and the through holes 315, 325 cut through the stacked layers 310, 325 at the same time by any of the previously described hole-forming processes. In some embodiments separate plug material portions can be provided to the through holes in various layers (here, absorbent layer 310 and transmission layer 320), for example as the holes are punched or cut in the layer. In some embodiments, the layers may be stacked and hole punched or cut together and accordingly a single portion of plug material can be provided extending through the holes 315, 325 of multiple layers.


Although the through holes 315 in the absorbent layer 310 and the through holes 325 in the transmission layer 320 are depicted as being centered and aligned one-to-one, other alignments can be used in other embodiments. For example, multiple smaller through holes 325 in the transmission layer 320 can be aligned with larger through hole 315 in the absorbent layer 310. Further, although the through holes 315 in the absorbent layer 310 are depicted as being larger than the through holes 325 in the transmission layer 320, in other embodiments the through holes 315, 325 may be substantially equal sizes or the through holes 325 in the transmission layer may be larger than the through holes 315 in the absorbent layer 310. In some embodiments, non-woven materials may require relatively larger holes (for example approximately 2 mm or larger) than woven materials in order for the holes to remain open under negative pressure. Depending on the amount of negative pressure applied to the dressing 300, the through holes in the layer closest to the patient tissue may be limited to a maximum diameter in order to prevent the formation of suction blisters by tissue pulled into the through holes. In some embodiments, the through holes 325 in the transmission layer 320 may have a diameter of approximately 1 mm or less to prevent the underlying tissue from being pulled into the through holes 325 when negative pressure is applied to the dressing 300, thereby preventing damage to the tissue and/or discomfort to the patient. In other embodiments, the through holes 325 may have a diameter of approximately 10 mm or less. The through holes 315 in the absorbent layer 310 can have a diameter of approximately 2 mm to approximately 10 mm in some embodiments. Although through holes 315, 325 are illustrated as being generally circular in shape, this is for purposes of illustration and other shapes can be used for through holes 315, 325 in other embodiments such as elliptical, square, rectangular, triangular, and hexagonal, to name a few.


In some embodiments, the through holes in one or both of the absorbent layer and transmission layer 320 may be susceptible to closing under negative pressure. Adhesive can be applied to the upper surface of the tissue contact layer 350 in some embodiments, and by contacting the transmission layer 320 such adhesive can assist in maintaining the openness of the through holes 325 in the transmission layer 320. Similarly, adhesive can be applied to the lower surface of the cover layer 345 in some embodiments, and by contacting the absorbent layer 310 such adhesive can assist in maintaining the openness of the through holes 315 in the absorbent layer 310. Adhesive can be applied between the absorbent layer 310 and the transmission layer 320 in some embodiments to assist in maintaining the openness of through holes 315, 325 in both layers. For example, in some embodiments the adhesive layer between the absorbent layer 310 and the transmission layer 320 may comprise an adhesive web or net. In other embodiments, the adhesive layer may comprise adhesive tape. Yet other embodiments may employ a hot melt adhesive a hot melt adhesive such as ethylene vinyl acetate (EVA). For example, EVA powder may be sprinkled over one or both of the layers 310, 320, which may then be heat bonded. Preferred embodiments of the adhesive layer are hydrophilic so as not to affect the transport of water and/or water-based solutions between the absorbent layer 310 and the transmission layer 320.


The absorbent layer 310 may be of a greater area than the transmission layer 320 in some embodiments, such that the absorbent layer 310 overlaps two or more edges of the transmission layer 320, thereby ensuring that the transmission layer does not contact the cover layer 345. This can provide an outer channel of the absorbent layer that is in direct contact with the tissue contact layer 350 that aids more rapid absorption of exudates to the absorbent layer. Furthermore, such an outer channel can ensure that no liquid is able to pool around the circumference of the wound cavity, which may otherwise seep through the seal around the perimeter of the dressing leading to the formation of leaks.


The cover layer 345 is preferably gas impermeable, but moisture vapor permeable, and can extend across the width of the wound dressing 300. The cover layer 345, which may for example be a polyurethane film having a pressure sensitive adhesive on one side, is impermeable to gas and this layer thus operates to cover the wound and to seal a wound cavity over which the wound dressing is placed. In this way an effective chamber is made between the cover layer 345 and a wound site where a negative pressure can be established. The cover layer 345 is preferably sealed to the tissue contact layer 350 in a border region 305 around the circumference of the dressing, ensuring that no air is drawn in through the border area, for example via adhesive or welding techniques. The cover layer 345 protects the wound or underlying tissue from external bacterial contamination (bacterial barrier) and allows liquid from wound exudates to be transferred through the layer and evaporated from the film outer surface. The cover layer 345 preferably comprises two layers; a polyurethane film and an adhesive pattern spread onto the film. Some embodiments may employ a polyurethane film (for example, Elastollan SP9109) or any other suitable material. For example, certain embodiments may comprise translucent or transparent 30 gsm EU33 film. An example of a cover contact layer adhesive spread is illustrated in FIG. 11 and discussed in more detail below. The polyurethane film is preferably moisture vapor permeable and may be manufactured from a material that has an increased water transmission rate when wet.


An orifice 365 is preferably provided in the cover layer 345 to allow a negative pressure to be applied to the dressing 300. A suction port 335 is preferably attached or sealed to the top of the cover layer 345 over the orifice 365 made or formed into the cover layer 345 to communicate negative pressure through the orifice 365. A length of tubing 340 may be coupled at a first end to the suction port 335 and at a second end to a pump unit (not shown) to allow transmission of negative pressure to the dressing 300 and, in some embodiments, to allow fluids to be pumped out of the dressing 300. The port 335 may be adhered and sealed to the cover layer 345 using an adhesive such as an acrylic, cyanoacrylate, epoxy, UV curable or hot melt adhesive. The illustrated embodiment of the port 335 can be formed from a soft polymer, for example a polyethylene, a polyvinyl chloride, a silicone or polyurethane having a hardness of 30 to 90 on the Shore A scale. However, the illustrated port 335 is intended to provide one example of a port suitable for use with the wound dressing 300 and not to limit the type of port usable with the dressing 300. In some embodiments, the port 335 may be made from a soft or conformable material, for example using the embodiments described in International Patent Application No. PCT/M2013/001469, filed May 22, 2013, titled “APPARATUSES AND METHODS FOR NEGATIVE PRESSURE WOUND THERAPY,” the entirety of which is hereby incorporated by reference.


Preferably the absorbent layer 310 includes at least one through hole 355 located so as to underlie the port 335. The through hole 355, while illustrated here as being larger than the hole through the cover layer 345, may in some embodiments be bigger or smaller than the hole 365 in cover layer 345. It will be appreciated that multiple openings could alternatively be utilized. Additionally should more than one port be utilized according to certain embodiments of the present disclosure one or multiple openings may be made in the absorbent layer 310 and the cover layer 345 in registration with each respective port. Although not essential to certain embodiments of the present disclosure the use of through holes in a super-absorbent material forming the absorbent layer 320 may provide a fluid flow pathway which remains unblocked in particular when the absorbent layer 310 is near saturation.


Accordingly, the port 335 is in direct fluid communication with the transmission layer 320 through orifice 365 and through hole 355. This allows the negative pressure applied to the port 335 to be communicated to the transmission layer 320 without passing through the absorbent layer 310, ensuring that the negative pressure applied to the wound site is not inhibited by the absorbent layer 310 as it absorbs wound exudates. In use, for example when negative pressure is applied to the dressing 300, a wound facing portion of the port 335 may thus come into contact with the transmission layer 320, which can thus aid in transmitting negative pressure to the wound site even when the absorbent layer 310 is filled with wound fluids. Some embodiments may have the cover layer 345 be at least partly adhered to the transmission layer 320. In some embodiments, the aperture 355 in the absorbent layer 310 is at least 1-2 mm larger than the diameter of the wound facing portion of the port 335. In other embodiments the aperture 355 in the absorbent layer 310 is smaller than the diameter of the wound facing portion of the port 335. In other embodiments, no aperture may be provided in the absorbent layer 310, or alternatively a plurality of apertures underlying the orifice 365 may be provided.


A filter element that is impermeable to liquids, but permeable to gases can be provided in or below the port 335 to act as a liquid barrier between the dressing 300 and the conduit 340 in some embodiments to ensure that no liquids are able to escape from the wound dressing 300. The filter element may also function as a bacterial barrier. The pore size can be approximately 0.2 μm. Suitable materials for the filter material of the filter element include 0.2 micron Gore™ expanded PTFE from the MMT range, PALL Versapore™ 200R, and Donaldson™ TX6628. Larger pore sizes can also be used but these may require a secondary filter layer to ensure full bioburden containment. As wound fluid contains lipids it is preferable, though not essential, to use an oleophobic filter membrane for example 1.0 micron MMT-332 prior to 0.2 micron MMT-323. This prevents the lipids from blocking the hydrophobic filter. The filter element can be attached or sealed to the port 335 and/or the cover layer 345 over the orifice 365. For example, the filter element may be molded into the port 335, or may be adhered to both the top of the cover layer 345 and bottom of the port 335 using an adhesive such as, but not limited to, a UV cured adhesive.


In particular for embodiments with a single port 335, it may be preferable for the port 335 to be located in an off-center position as illustrated in FIGS. 3A-C and in FIG. 1. Such a location may permit the dressing 300 to be positioned onto a patient such that the port 335 is raised in relation to the remainder of the dressing 2100. So positioned, the port 335 may be less likely to come into contact with wound fluids that could prematurely occlude the port 335 so as to impair the transmission of negative pressure to the wound site.


Some embodiments may be manufactured without the port 335 and may include at least one area for attaching a port. For example, the port may simply be an opening in the cover layer 345 for attaching a separate port member, and the opening may be preformed in the cover layer 345 or formed by a clinician by cutting, puncturing, or tearing the cover layer 345.


In some embodiments, the tissue contact layer 350 may be flat and the cover layer 345 may be contoured over the inner layers of the dressing 300. The absorbent layer 310 may be about 1.5 times thicker than the transmission layer 320 in some embodiments.



FIGS. 4A-4C illustrate another embodiment of a wound dressing 400 configured for enhanced tissue visibility. FIG. 4A illustrates a top view of the wound dressing 400, FIG. 4B illustrates a cross-sectional view of the wound dressing 400, and FIG. 4C illustrates an exploded view of various layers of the wound dressing 400. The wound dressing 400 can be located over a wound site or potentially wound-forming tissue site to be treated as described above. In some embodiments, the dressing 400 comprises a cover layer 445 attached to a tissue contact layer 450, for example any of the cover layer or tissue contact layer embodiments described above or below. These two layers 445, 450 can be joined or sealed together around a perimeter 405 so as to define an interior space or chamber in which therapeutic negative pressure can exist. This interior space or chamber may include absorbent layer 410 and transmission layer 420, which can be any of the absorbent materials or transmission materials described above or below. A port 435 and conduit 440 can be attached to the dressing 400 overlying an orifice 465 in the cover layer 445 and a through hole 455 in the absorbent layer 410 as described above with respect to FIGS. 3A-3C for transmission of negative pressure from a pump to the dressing 400.


The absorbent layer 410 includes a number of through holes 415 arranged in a repeating pattern. The transmission layer 320 includes an additional number of through holes 425 of substantially the same size as the through holes 415 in the absorbent layer 410 and arranged in a similar repeating pattern. In some embodiments, the through holes 415 in the absorbent layer 410 and the through holes 425 in the transmission layer 420 can be aligned or substantially aligned to form viewing portals 430 through the internal layers of the dressing 400. As described above, some or all of the through holes 415, 425 may comprise a plug material. As described above, due to the transparency or translucency of the cover layer 445 and tissue contact layer 450, the viewing portals 430 can permit viewing of tissue beneath the wound dressing through the wound cover when the wound dressing is applied to a patient, for example enabling a clinician to assess characteristics of and changes in tissue underlying the dressing 400. In the illustrated embodiment, the transmission layer 420 has no through holes underlying the through hole 455 in the absorbent layer 410 over which the port 435 is applied. However, in other embodiments the pattern of through holes 425 in the transmission layer 420 may continue under the through hole 455 in the absorbent layer 410.



FIGS. 5A-5C illustrate another embodiment of a wound dressing 500 configured for enhanced tissue visibility. FIG. 5A illustrates a top view of the wound dressing 500, FIG. 5B illustrates a cross-sectional view of the wound dressing 500, and FIG. 5C illustrates an exploded view of various layers of the wound dressing 500. The wound dressing 500 can be located over a wound site or potentially wound-forming tissue site to be treated as described above. In some embodiments, the dressing 500 comprises a cover layer 545 attached to a tissue contact layer 550, for example any of the cover layer or tissue contact layer embodiments described above or below. These two layers 545, 550 can be joined or sealed together around a perimeter 505 so as to define an interior space or chamber in which therapeutic negative pressure can exist. This interior space or chamber may include a single material layer 510, which can be any of the absorbent materials or transmission materials described above or below. A port 535 and conduit 540 can be attached to the dressing 500 overlying the material layer 510 as described above with respect to FIGS. 3A-3C for transmission of negative pressure from a pump to the dressing 500.


The material layer 510 can include a number of through holes 515 forming viewing portals 530 through the dressing. As described above, some or all of the through holes 515 may comprise a plug material. As described above, due to the transparency or translucency of the cover layer 545 and tissue contact layer 550, the viewing portals 530 can permit viewing of tissue beneath the wound dressing through the wound cover when the wound dressing is applied to a patient, for example enabling a clinician to assess characteristics of and changes in tissue underlying the dressing 500. The through holes 515 can be arranged in a repeating pattern, here illustrated as hexagonal through holes 515 forming a honeycomb pattern, across substantially all of the area of the material layer 510. The pattern can be discontinued in some embodiments in an area underlying the port 535 so that the underlying tissue contact layer 550 does not come into contact with and occlude the port 535 when negative pressure is applied to the dressing 500.



FIGS. 6A-6C illustrate various embodiments of a wound dressing configured for enhanced tissue visibility. FIG. 6A illustrates a top view of the wound dressing 600A showing the perimeter 605 of a cover layer and tissue contact layer, a material layer 610 below the cover layer, and a pattern of through holes 615 in the material layer. The through holes 615 are illustrated in FIG. 6A as being a single line of six substantially equally sized holes. FIG. 6B illustrates a top view of another embodiment of the wound dressing 600B showing the perimeter 605 of a cover layer and backing layer, the material layer 610 below the cover layer, and a second embodiment of the pattern of through holes 615 in the material layer. The through holes 615 are illustrated in FIG. 6B as being three rows of six substantially equally sized holes. FIG. 6C illustrates a top view of another embodiment of the wound dressing 600C showing the perimeter 605 of a cover layer and backing layer, a material layer 610 below the cover layer, and a pattern of through holes 615 in the material layer. The through holes 615 are illustrated in FIG. 6C as being a circle of substantially equally sized holes positioned around a center hole.


In some embodiments, a port can be placed over any of the holes in the patterns illustrated in FIGS. 6A-6C. Though not illustrated, through holes in a layer underneath the illustrated material layer 610 may be smaller than the through holes 615 in the material layer 610. Viewing portals can be formed through the dressing by aligning at least a portion of one or more holes in a lower layer with one of the through holes 615 in the material layer 610. As described above, some or all of the through holes 615 may comprise a plug material.



FIG. 7 illustrates a top view of another embodiment of a wound dressing 700 configured for enhanced tissue visibility. The wound dressing 700 can be located over a wound site or potentially wound-forming tissue site to be treated as described above. In some embodiments, the dressing 700 comprises a cover layer attached to a tissue contact layer, for example any of the cover layer or tissue contact layer embodiments described above or below, joined or sealed together around a perimeter 705 so as to define an interior space or chamber in which therapeutic negative pressure can exist. This interior space or chamber may include an absorbent layer 710 and a transmission layer positioned beneath the absorbent layer, which can be any of the absorbent materials or transmission materials described above or below. A port 735 and conduit 740 can be attached to the dressing 700 overlying one of the through holes 715 in the absorbent layer 710 for transmission of negative pressure from a pump to the dressing 700.


The absorbent layer 710 includes a number of through holes 715 arranged in a pattern including three rows of seven substantially equally sized holes 715. The transmission layer includes an additional number of through holes 725 of a substantially smaller size than the through holes 715 in the absorbent layer 710. The through holes 725 in the transmission layer are arranged in a repeating pattern. When the transmission layer and absorbent layer 710 are aligned under the cover layer, multiple through holes 725 in the transmission layer can be visible through each of the through holes 715 in the absorbent layer 710 to form viewing portals 730 through the dressing to the underlying tissue. As described above, due to the transparency or translucency of the cover layer and tissue contact layer, the viewing portals 730 can permit viewing of tissue beneath the wound dressing through the wound cover when the wound dressing is applied to a patient, for example enabling a clinician to assess characteristics of and changes in tissue underlying the dressing 700. The repeating pattern of holes 725 in the transmission layer may or may not extend under the port 735 in various embodiments. As described above, some or all of the through holes 725 may comprise a plug material.


III. Example Materials



FIGS. 8A and 8B illustrate one embodiment of spacer layer material suitable for use as a transmission layer, which may be used in any of the dressing embodiments described above. The spacer or transmission material is preferably formed of a material having a three dimensional structure, and may have a top layer and a bottom layer comprising a knit pattern. For example, a knitted or woven spacer fabric (for example Baltex 7970 weft knitted polyester) or a non-woven fabric could be used. The top and bottom fabric layers may comprise polyester, such as 84/144 textured polyester or a flat denier polyester. Other materials and other linear mass densities of fiber could of course be used. In some embodiments, the top and bottom fabric layers may be the same pattern and the same material, and in other embodiments they may be different patterns and/or different materials. The top fabric layer may have more filaments in a yarn used to form it than the number of filaments making up the yarn used to form the bottom fabric layer, in order to control moisture flow across the transmission layer. Particularly, by having a filament count greater in the top layer, that is to say, the top layer is made from a yarn having more filaments than the yarn used in the bottom layer, liquid tends to be wicked along the top layer more than the bottom layer. FIG. 8A illustrates one possible knit pattern for a top or bottom fabric layer.


As illustrated in the side view of FIG. 8B, between the top and bottom fabric layers may be a plurality of filaments. The filaments may comprise a monofilament fiber or a multistrand fiber, and may be knitted polyester viscose or cellulose. In some embodiments, a majority of the filaments, by volume, may extend vertically (that is, perpendicular to the plane of the top and bottom layers), or substantially or generally vertically. In another embodiment, 80%-90% (or approximately 80% to approximately 90%) of the filaments or more, by volume, may extend vertically, or substantially or generally vertically. In another embodiment, all or substantially all of the filaments, by volume, may extend vertically, or substantially or generally vertically. In some embodiments, a majority, 80%-90% (or approximately 80% to approximately 90%) of the filaments or more, or even all or substantially all of the filaments, extend upward from the bottom fabric layer and/or downward from the top fabric layer, and in some embodiments, such filaments extend over a length more than half the distance between the top and bottom fabric layers. In some embodiments, a majority, 80%-90% (or approximately 80% to approximately 90%) of the filaments or more, or even all or substantially all of the filaments, span a distance that is greater in a direction perpendicular to the top and bottom fabric layers (a vertical direction) than in a direction parallel to the top and bottom fabric layers (a horizontal direction). The orientation of such filaments may promote vertical wicking of fluid through the spacer layer. In some embodiments, the ratio of the amount of fluid wicked vertically through the spacer material to the amount of fluid wicked laterally across the spacer material when under negative pressure may be 2:1 or more, or approximately 2:1 or more, or may be up to 10:1 or more, or approximately 10:1 or more, in some embodiments. Such filaments may also keep the top and bottom layers spaced apart when exposed to compressive forces or negative pressure.



FIGS. 9A and 9B illustrate one embodiment of acquisition distribution layer material which may be suitable for use as a transmission layer in any of the dressing embodiments described above. To those versed in the art of acquisition distribution layers it would be obvious that other ADL materials may be used to achieve a similar effect. Such ADL layers may be composed of multiple fibre types and be complex in structure and design. The ADL material, in an uncompressed state, may be 0.1 mm to 4 mm thick, or approximately 0.1 mm to approximately 4 mm thick, and in some embodiments may be 1.2 mm thick, or approximately 1.2 mm thick, in an uncompressed state. The ADL material may comprise a plurality of loosely packed fibers, which may be arranged in a substantially horizontal fibrous network.


In some embodiments, the ADL material may consist of a mix of two fiber types. One may be a flat fiber which may be 20 μm to 50 μm in width, or approximately 20


μm to approximately 50 μm in width, and may comprise a cellulosic based material. The other fiber may be a two component fiber that has an inner core that is 8 μm to 10 μm in diameter, or approximately is 8 μm to approximately 10 μm in diameter, and an outer layer with a thickness of 1 μm to 2 μm, or approximately 1 μm to approximately 2μm. The two component fiber may be a mix of a polyethylene (PE) type material, and polyethylene terephthalate (PET). In some embodiments the inner core of the two component fiber may be PET and the outer layer may be PE. The PE/PET fibers may have a smooth surface morphology, while the cellulosic fibers may have a relatively rougher surface morphology. In some embodiments the ADL material may comprise about 60% to about 90% cellulosic fibers, for example approximately 75% cellulosic fibers, and may comprise about 10% to about 40% PE/PET fibers, for example approximately 25% PE/PET fibers.



FIG. 9A illustrates a backscatter scanning electron microscope (SEM) plan view of a sample portion of acquisition distribution layer material at 140× magnification. FIG. 9B illustrates an SEM cross sectional view at 250× magnification. As illustrated in FIG. 9B, a majority of the fiber volume may extend horizontally (that is, parallel to the plane of the top and bottom surfaces of the material), or substantially or generally horizontally. In another embodiment, 80%-90% (or approximately 80% to approximately 90%) or more of the fiber volume may extend horizontally, or substantially or generally horizontally. In another embodiment, all or substantially all of the fiber volume may extend horizontally, or substantially or generally horizontally. In some embodiments, a majority, 80%-90% (or approximately 80% to approximately 90%) of the fibers or more, or even all or substantially all of the fibers, span a distance perpendicular to the thickness of the ADL material (a horizontal or lateral distance) that is greater than the thickness of the ADL material. In some embodiments, the horizontal or lateral distance spanned by such fibers is 2 times (or about 2 times) or more, 3 times (or about 3 times) or more, 4 times (or about 4 times) or more, 5 times (or about 5 times) or more, or 10 times (or about 10 times) or more the thickness of the ADL material. The orientation of such fibers may promote lateral wicking of fluid through the ADL material. This may more evenly distribute fluid such as wound exudate throughout the ADL material. In some embodiments, the ratio of the amount of fluid wicked laterally across the ADL material to the amount of fluid wicked vertically through the ADL material under negative pressure may be 2:1 or more, or approximately 2:1 or more, or may be up to 10:1 or more, or approximately 10:1 or more, in some embodiments.



FIGS. 10A and 10B illustrate one embodiment of absorbent layer material which may be used in any of the dressing embodiments described above. FIG. 10A illustrates a three dimensional microtomographic cross sectional view of a sample of absorbent material, depicting a fibrous composition interspersed with superabsorbent particles.



FIG. 10B is a cross sectional schematic diagram of an embodiment of the absorbent material illustrating a plurality of layers within the absorbent material. The absorbent material may have a textured layer 4210 on one side of a fibrous network, the fibrous network defining the bulk of the absorbent material and comprising layers 4220, 4240, and 4250. Superabsorbent particles 4230 may be dispersed throughout layers 4220, 4240, and 4250. The textured layer 4210, also referred to as the “tissue dispersant layer” in above portions of this specification, may be configured to laterally transmit fluid. Though depicted as the lowermost layer of the absorbent material, the textured layer 4210 may in some embodiments be positioned as the uppermost layer of the absorbent material, and in some embodiments may be positioned as both the lowermost and uppermost layers of the absorbent material. The textured layer 4210 may comprise flat fibers 20 μm to 50 μm in width, or approximately 20 μm to approximately 50 μm in width. The textured layer 4210 may comprise 1 to 2 or approximately 1 to approximately 2 layers of the flat fibers, and the textured layer 4210 may have an overall thickness of 0.04 mm, or approximately 0.04 mm.


The bulk of the absorbent material, comprising layers 4220, 4240, and 4250, may have a thickness of 1.7 mm, or approximately 1.7 mm, or may have a thickness in the range of 0.5 mm to 5.0 mm, or about 0.5 mm to about 5.0 mm. The bulk of the absorbent material may comprise a mix of two fiber types arranged in a fibrous network, for example the cellulosic fiber having a width of 20 μm to 50 μm, or approximately 20 μm to approximately 50 μm, and the PE/PET composite fiber, described above with respect to the ADL material. The superabsorbent particles 4230 may be irregularly shaped and varied in size, and may have a diameter of up to 1 mm, or approximately 1 mm. The superabsorbent particles 4230 may comprise a sodium acrylate type material. There may be relatively fewer superabsorbent particles in a portion of the uppermost surface of the bulk of the absorbent material (the surface of layer 4250 opposite the textured layer 4210), for example in an uppermost surface having a thickness of approximately 0.1 mm.


Layer 4220 may be a liquid absorption layer configured to draw liquid upward through the material towards layers 4240 and 4250. Layer 4240 may be a storage layer configured to hold absorbed liquid. Layer 4220 may be a liquid distribution layer configured to apply a “reverse suction” effect to the liquid storage layer 4240 in order to inhibit (or substantially inhibit) absorbed liquid from leaking back down through the lower layers of the absorbent material, a phenomenon which is commonly known as “back wetting.”


Superabsorbent particles 4230 may be distributed primarily within the storage layer, may extend partially into the absorption layer 4220 and liquid distribution layer 4250, or may be distributed evenly (or substantially evenly) throughout the layers. The layers 4220, 4240, and 4250 may overlap with a portion of adjacent layers, and may or may not be separable.



FIG. 11 illustrates one embodiment of an adhesive spread on approximately one square centimeter of a film material, which may be used as the cover or backing layer in any of the dressing embodiments described above. The adhesive on the film has been covered with carbon powder for ease of illustrating the spread of the adhesive. The adhesive may comprise, for example, an acrylate type adhesive, for example K5 adhesive, and may be laid down in a criss cross pattern. In some embodiments, the adhesive material may cover approximately 45.5%±approximately 1.3% of the film surface. The pattern and coverage of the adhesive may vary so long as the configuration is suitable for desired vapor permeability.


IV. Example Dressings with Plug Material



FIGS. 12A-12E are photographic representations of various embodiments of a wound dressing configured for enhanced tissue visibility through plug material. As described above, the plug material can be any soft, transparent or translucent, and optionally hydrophobic material, with one example being silicone. Plug material can be positioned within some or all through holes in the dressing.



FIG. 12A illustrates one embodiment of a wound dressing having at least one internal layer positioned between a cover layer and a wound contact layer having a sealed perimeter, the at least one internal layer having a first through hole positioned so as to underlie a suction port (not attached in this illustration) and a viewing window matrix of additional through holes windows through the dressing. In this embodiment, each hole in the viewing window matrix is provided with a pillar of plug material. The through hole to underlie the suction port may not be provided with plug material. In certain embodiments, the at least one internal layer includes two or more layers (e.g., a transmission layer and an absorbent layer over the transmission layer), and the pillar of plug material can extend fully through both of the layers. In some embodiments, the through holes of the transmission layer and the absorbent layer may have the same dimension or diameter. In other implementations, the pillar of plug material can extend through just one layer, or at least partially through one or more layers. The pillars of plug material can have a diameter of 10 mm (or approximately 10 mm) in some examples.



FIG. 12B illustrates another embodiment of a wound dressing having at least one internal layer with a viewing window matrix having the through holes filled with pillars of plug material. The embodiment of FIG. 12B includes a flexible suction adapter attached to the cover layer of the dressing over the first through hole. FIG. 12C illustrates the embodiment of FIG. 12B with the suction adapter attached to a portable, compact negative pressure pump. In other embodiments a length of extension tubing may be coupled between the pump and the suction adapter, and various other negative pressure pumps may be coupled to the system in place of the illustrated compact pump.



FIG. 12D illustrates a close-up view of a portion of the viewing window matrix of the embodiment of FIG. 12B, each through hole in the viewing matrix having a pillar of plug material extending through both an absorbent layer and a transmission layer positioned underneath the absorbent layer. The through holes forming the viewing windows can be aligned and can have a diameter of 10 mm (or approximately 10 mm), and the pillars of plug material can have a diameter of 10 mm (or approximately 10 mm) in some examples.



FIG. 12E illustrates a visual example of the enhanced visibility provided by a dressing with viewing windows such as is described herein. The illustrated dressing is placed over a surface with a variety of markings that are clearly visible through the viewing windows. Accordingly, a clinician can use such a dressing to visually assess the condition of tissue underlying the dressing.


In an alternate embodiment, a dressing can include a transmission layer that is transparent, translucent, or contains more open areas (e.g., a less dense weave) with holes smaller than approximately 10 mm in diameter, and the pillars may only extend through the absorbent layer. Accordingly, the transmission layer may extend underneath the pillars of plug material in the absorbent layer, thereby providing enhanced transmission of negative pressure and/or spread of wound exudate compared to embodiments having plug material positioned within the transmission layer.


In another alternate embodiment, rather than having the plug material formed as pillars through one or more layers, a dressing may have a layer or structure of transparent or translucent material (for example, silicone) with an array of absorbent or superabsorbent material portions. For instance, the transparent or translucent layer or structure may form an interconnected frame extending across the length and width of the wound dressing, and have a matrix of holes or spaces within the frame where absorbent material can be provided to fill the holes or spaces. In some examples, the transparent or translucent layer may take the same shape as any of the embodiments of the absorbent layer previously described, and the superabsorbent material portions may take the shape of any of the embodiments of the pillars previously described. Alternatively, a dressing may comprise alternating struts, strips or bands of transparent or translucent material and struts, strips or bands of absorbent material. For example, a wound dressing layer may comprise diagonal alternating bands of transparent or translucent material and absorbent material. In any of the aforementioned embodiments, a transmission layer may be provided under the transparent or translucent material and the absorbent material for transmission of negative pressure, and a suction adapter or other negative pressure source may be provided to communicate negative pressure to a wound site, optionally through a through hole in either the absorbent material or in the transparent or translucent material.


V. Terminology


Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.


While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated and/or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure.


Although the present disclosure includes certain embodiments, examples and applications, it will be understood by those skilled in the art that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof, including embodiments which do not provide all of the features and advantages set forth herein. Accordingly, the scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments herein, and may be defined by claims as presented herein or as presented in the future.

Claims
  • 1. A wound dressing comprising: a material layer;a plurality of plug materials extending vertically through a thickness of the material layer; anda cover layer positioned above the material layer, the cover layer configured to form a negative pressure chamber underneath the cover layer, the cover layer couplable to a source of negative pressure configured to create negative pressure in the negative pressure chamber.
  • 2. The wound dressing of claim 1, further comprising a port configured to communicate negative pressure to the negative pressure chamber.
  • 3. The wound dressing of claim 2, wherein the port is configured to be attached to the cover layer.
  • 4. The wound dressing of claim 1, wherein the material layer comprises a foam.
  • 5. The wound dressing of claim 1, wherein the cover layer is transparent or translucent.
  • 6. The wound dressing of claim 1, wherein the material layer comprises a plurality of through holes extending vertically through the thickness of the material layer, wherein the plug materials are positioned within at least some of the plurality of through holes.
  • 7. The wound dressing of claim 6, wherein the through holes are configured to permit viewing of tissue beneath the wound dressing through the cover layer when the wound dressing is applied to a patient.
  • 8. The wound dressing of claim 1, wherein the plug materials are cylindrical.
  • 9. A method of treating a wound, the method comprising: applying a wound dressing to the wound, the wound dressing comprising: a material layer;a plurality of plug materials extending vertically through a thickness of the material layer; anda cover layer positioned above the material layer, the cover layer configured to form a negative pressure chamber underneath the cover layer, the cover layer couplable to a source of negative pressure configured to create negative pressure in the negative pressure chamber.
  • 10. The method of claim 9, wherein the wound dressing further comprises a port configured to communicate negative pressure to the negative pressure chamber.
  • 11. The method of claim 10, wherein the port is configured to be attached to the cover layer.
  • 12. The method of claim 9, wherein the material layer comprises a foam.
  • 13. The method of claim 9, wherein the cover layer is transparent or translucent.
  • 14. The method of claim 9, wherein the material layer comprises a plurality of through holes extending vertically through the thickness of the material layer, wherein the plug materials are positioned within at least some of the plurality of through holes.
  • 15. The method of claim 14, further comprising visualizing tissue beneath the wound dressing through the cover layer through the through holes.
  • 16. The method of claim 9, wherein the plug materials are cylindrical.
  • 17. A dressing, comprising: a foam layer;a plurality of cores extending substantially through the foam layer; anda drape sealable over the foam layer and a wound bed, the drape defining a substantially-airtight volume between the drape and the wound bed that contains the foam layer, the drape couplable to a pump operable to create a negative pressure in the substantially-airtight volume.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/319,743, filed on Dec. 16, 2016, which is a national stage application of International Patent Application No. PCT/EP2015/063373, filed on Jun. 15, 2015, titled “WOUND DRESSING AND METHOD OF TREATMENT,” which claims priority to U.S. Provisional Application Ser. No. 62/013989 filed on Jun. 18, 2014, titled “WOUND DRESSING AND METHOD OF TREATMENT,” and U.S. Provisional Application Ser. No. 62/085774, filed on Dec. 1, 2014, titled “WOUND DRESSING AND METHOD OF TREATMENT.”

US Referenced Citations (561)
Number Name Date Kind
3972328 Chen Aug 1976 A
4029598 Neisius et al. Jun 1977 A
4728499 Fehder Mar 1988 A
4798603 Meyer et al. Jan 1989 A
4813942 Alvarez Mar 1989 A
4834735 Alemany et al. May 1989 A
4846164 Martz Jul 1989 A
4968181 Goldman Nov 1990 A
4973325 Sherrod et al. Nov 1990 A
4988344 Reising et al. Jan 1991 A
4988345 Reising Jan 1991 A
5021050 Iskra Jun 1991 A
5037409 Chen et al. Aug 1991 A
5056510 Gilman Oct 1991 A
5065600 Byles Nov 1991 A
5124197 Bernardin et al. Jun 1992 A
5149334 Lahrman et al. Sep 1992 A
5149469 Komatsuzaki et al. Sep 1992 A
5151091 Glaug et al. Sep 1992 A
5171391 Chmielewski et al. Dec 1992 A
5175046 Nguyen Dec 1992 A
5181905 Flam Jan 1993 A
5217445 Young et al. Jun 1993 A
5236427 Hamajima et al. Aug 1993 A
5238732 Krishnan Aug 1993 A
5242435 Murji et al. Sep 1993 A
5257982 Cohen et al. Nov 1993 A
5271987 Iskra Dec 1993 A
5281208 Thompson et al. Jan 1994 A
5294478 Wanek et al. Mar 1994 A
5296290 Brassington Mar 1994 A
5314743 Meirowitz et al. May 1994 A
5318554 Young et al. Jun 1994 A
5330456 Robinson Jul 1994 A
5342336 Meirowitz et al. Aug 1994 A
5348547 Payne et al. Sep 1994 A
5356405 Thompson et al. Oct 1994 A
5360420 Cook et al. Nov 1994 A
5364382 Latimer et al. Nov 1994 A
5366451 Levesque Nov 1994 A
5368909 Langdon et al. Nov 1994 A
5368926 Thompson et al. Nov 1994 A
5374260 Lemay et al. Dec 1994 A
5382245 Thompson et al. Jan 1995 A
5387208 Ashton et al. Feb 1995 A
5397316 LaVon et al. Mar 1995 A
5401267 Couture-Dorschner et al. Mar 1995 A
5425725 Tanzer et al. Jun 1995 A
5431643 Ouellette et al. Jul 1995 A
5454800 Hirt et al. Oct 1995 A
5465735 Patel Nov 1995 A
5470326 Dabi et al. Nov 1995 A
H1511 Chappell et al. Dec 1995 H
5486167 Dragoo et al. Jan 1996 A
5500270 Langdon et al. Mar 1996 A
5505719 Cohen et al. Apr 1996 A
5509914 Osborn, III Apr 1996 A
5514120 Johnston et al. May 1996 A
5525407 Yang Jun 1996 A
5536264 Hsueh et al. Jul 1996 A
5538500 Peterson Jul 1996 A
H1585 Ahr Aug 1996 H
5545155 Hseih et al. Aug 1996 A
5549584 Gross Aug 1996 A
5549589 Horney et al. Aug 1996 A
5562107 Lavender et al. Oct 1996 A
5562646 Goldman et al. Oct 1996 A
5562650 Everett et al. Oct 1996 A
5591148 McFall et al. Jan 1997 A
5591149 Cree et al. Jan 1997 A
5603707 Trombetta et al. Feb 1997 A
5609588 DiPalma et al. Mar 1997 A
5613960 Mizutani Mar 1997 A
5614283 Pontis et al. Mar 1997 A
5614295 Quincy, III et al. Mar 1997 A
5628736 Thompson May 1997 A
5632731 Patel May 1997 A
H1657 Hammons et al. Jun 1997 H
5634915 Osterdahl Jun 1997 A
5643238 Baker Jul 1997 A
5648142 Phillips Jul 1997 A
5649915 Chauvette et al. Jul 1997 A
5649916 DiPalma et al. Jul 1997 A
5665082 Boulanger Sep 1997 A
5669895 Murakami et al. Sep 1997 A
5675079 Gilman et al. Oct 1997 A
5700254 McDowall et al. Dec 1997 A
5704905 Jensen et al. Jan 1998 A
5707499 Joshi et al. Jan 1998 A
5716703 Payne Feb 1998 A
5728084 Palumbo et al. Mar 1998 A
5728085 Widlund et al. Mar 1998 A
5733273 Ahr Mar 1998 A
5752945 Mosley et al. May 1998 A
5759570 Arnold Jun 1998 A
5762641 Bewick-Sonntag et al. Jun 1998 A
5788684 Abuto et al. Aug 1998 A
5801107 Everhart et al. Sep 1998 A
5810798 Finch et al. Sep 1998 A
5817081 LaVon et al. Oct 1998 A
5827213 Jensen Oct 1998 A
5827254 Trombetta et al. Oct 1998 A
5830202 Bogdanski et al. Nov 1998 A
5837627 Halabisky et al. Nov 1998 A
5843025 Shaari Dec 1998 A
5843064 Koczab Dec 1998 A
5852126 Barnard et al. Dec 1998 A
5855572 Schmidt Jan 1999 A
5865822 Hamajima et al. Feb 1999 A
5865824 Chen et al. Feb 1999 A
5873867 Coles et al. Feb 1999 A
5877097 West et al. Mar 1999 A
5891120 Chmielewski Apr 1999 A
5895379 Litchholt et al. Apr 1999 A
5897541 Uitenbrock et al. Apr 1999 A
5916507 Dabi et al. Jun 1999 A
5925026 Arteman et al. Jul 1999 A
5931823 Stokes et al. Aug 1999 A
5938995 Koltisko, Jr. et al. Aug 1999 A
5941863 Guidotti et al. Aug 1999 A
5947945 Cree et al. Sep 1999 A
5951535 Fujiwara et al. Sep 1999 A
5961506 Guidotti et al. Oct 1999 A
5968027 Cole et al. Oct 1999 A
5989478 Ouellette et al. Nov 1999 A
6022610 Phan et al. Feb 2000 A
6037518 Guidotti et al. Mar 2000 A
6060638 Paul et al. May 2000 A
6068620 Chmielewski May 2000 A
6071267 Zamierowski Jun 2000 A
6077526 Scully et al. Jun 2000 A
6096015 Yeo et al. Aug 2000 A
6103953 Cree et al. Aug 2000 A
6103954 Grondin et al. Aug 2000 A
6107539 Palumbo et al. Aug 2000 A
6117523 Sugahara Sep 2000 A
6127595 Makoui et al. Oct 2000 A
6168849 Braverman et al. Jan 2001 B1
6191340 Carlucci et al. Feb 2001 B1
6206865 Chen et al. Mar 2001 B1
6235966 Magnusson et al. May 2001 B1
6264776 DiPalma Jul 2001 B1
6294710 Schmidt et al. Sep 2001 B1
6297423 Schoenfeldt et al. Oct 2001 B1
6344036 Ivansson Feb 2002 B1
6362390 Carlucci et al. Mar 2002 B1
6369292 Strack et al. Apr 2002 B1
6372952 Lash et al. Apr 2002 B1
6403857 Gross et al. Jun 2002 B1
6461339 Sugahara Oct 2002 B1
6497689 Schmidt et al. Dec 2002 B1
6506175 Goldstein Jan 2003 B1
6506960 Young et al. Jan 2003 B1
6521813 Chihani Feb 2003 B1
6534149 Daley et al. Mar 2003 B1
6545194 Schmidt et al. Apr 2003 B1
6551295 Schmidt et al. Apr 2003 B1
6552244 Jacques et al. Apr 2003 B1
6570057 Schmidt et al. May 2003 B1
6570058 Fuchs et al. May 2003 B1
6573424 Raidel et al. Jun 2003 B1
6586653 Graeme, III et al. Jul 2003 B2
6610898 Magnusson et al. Aug 2003 B1
6610903 Latimer et al. Aug 2003 B1
6613028 Daley et al. Sep 2003 B1
6613953 Altura Sep 2003 B1
6613955 Lindsay et al. Sep 2003 B1
6626891 Ohmstede Sep 2003 B2
6630611 Malowaniec Oct 2003 B1
6664439 Arndt et al. Dec 2003 B1
6683229 Ehrnsperger et al. Jan 2004 B1
6685681 Lockwood et al. Feb 2004 B2
6719742 McCormack et al. Apr 2004 B1
6727403 Ehrnsperger et al. Apr 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6762337 Boukanov et al. Jul 2004 B2
6764459 Donaldson Jul 2004 B1
6783837 Creagan et al. Aug 2004 B1
6835192 Guidotti et al. Dec 2004 B1
6838589 Liedtke et al. Jan 2005 B2
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
6979324 Bybordi et al. Dec 2005 B2
7004915 Boynton et al. Feb 2006 B2
7049478 Smith et al. May 2006 B1
7070584 Johnson et al. Jul 2006 B2
7108683 Zamierowski Sep 2006 B2
7112712 Ancell Sep 2006 B1
7122023 Hinoki Oct 2006 B1
7216651 Argenta et al. May 2007 B2
7361184 Joshi Apr 2008 B2
7381859 Hunt et al. Jun 2008 B2
7429689 Chen et al. Sep 2008 B2
7511187 Kelly Mar 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7605298 Bechert et al. Oct 2009 B2
7612248 Burton et al. Nov 2009 B2
7615036 Joshi et al. Nov 2009 B2
7622629 Aail Nov 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7699823 Haggstrom et al. Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7718249 Russell et al. May 2010 B2
7722582 Lina et al. May 2010 B2
7749531 Booher Jul 2010 B2
7759537 Bishop et al. Jul 2010 B2
7759539 Shaw et al. Jul 2010 B2
7775998 Riesinger Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7811269 Boynton et al. Oct 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7838723 Schmidt et al. Nov 2010 B1
7846141 Weston Dec 2010 B2
7910791 Coffey Mar 2011 B2
7922703 Riesinger Apr 2011 B2
7959624 Riesinger Jun 2011 B2
7964766 Blott et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
7982087 Greener et al. Jul 2011 B2
8021347 Vitaris et al. Sep 2011 B2
8034037 Adams et al. Oct 2011 B2
8062272 Weston Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8092436 Christensen Jan 2012 B2
8118794 Weston et al. Feb 2012 B2
8147468 Barta et al. Apr 2012 B2
8152785 Vitaris Apr 2012 B2
8158844 McNeil Apr 2012 B2
8162907 Heagle Apr 2012 B2
8188331 Barta et al. May 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8212101 Propp Jul 2012 B2
8235972 Adahan Aug 2012 B2
8241261 Randolph et al. Aug 2012 B2
8252971 Aali et al. Aug 2012 B2
8282611 Weston Oct 2012 B2
8298200 Vess et al. Oct 2012 B2
8303552 Weston Nov 2012 B2
8314283 Kingsford et al. Nov 2012 B2
8372049 Jaeb et al. Feb 2013 B2
8372050 Jaeb et al. Feb 2013 B2
8399730 Kazala, Jr. et al. Mar 2013 B2
8404921 Lee et al. Mar 2013 B2
8425478 Olson Apr 2013 B2
8444612 Patel et al. May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8535296 Blott et al. Sep 2013 B2
8540688 Eckstein et al. Sep 2013 B2
8545466 Andresen et al. Oct 2013 B2
8568386 Malhi Oct 2013 B2
8628505 Weston Jan 2014 B2
8641691 Fink Feb 2014 B2
8663198 Buan et al. Mar 2014 B2
8680360 Greener et al. Mar 2014 B2
8715256 Greener May 2014 B2
8764732 Hartwell Jul 2014 B2
8771244 Eckstein et al. Jul 2014 B2
8791316 Greener Jul 2014 B2
8795243 Weston Aug 2014 B2
8795247 Bennett et al. Aug 2014 B2
8795800 Evans Aug 2014 B2
8801685 Armstrong et al. Aug 2014 B2
8808274 Hartwell Aug 2014 B2
8814842 Coulthard et al. Aug 2014 B2
8829263 Haggstrom et al. Sep 2014 B2
8834451 Blott et al. Sep 2014 B2
8834452 Hudspeth et al. Sep 2014 B2
8956336 Haggstrom et al. Feb 2015 B2
9061095 Adie et al. Jun 2015 B2
9067003 Buan et al. Jun 2015 B2
9127665 Locke et al. Sep 2015 B2
9168330 Joshi et al. Oct 2015 B2
9199012 Vitaris et al. Dec 2015 B2
9220822 Hartwell et al. Dec 2015 B2
9283118 Locke et al. Mar 2016 B2
9302033 Riesinger Apr 2016 B2
9327065 Alberti et al. May 2016 B2
9375353 Vitaris et al. Jun 2016 B2
9375521 Hudspeth et al. Jun 2016 B2
9381283 Adams et al. Jul 2016 B2
9427505 Askem et al. Aug 2016 B2
9446178 Blott et al. Sep 2016 B2
9452248 Blott et al. Sep 2016 B2
9474653 Luckemeyer et al. Oct 2016 B2
9669138 Joshi et al. Jun 2017 B2
9682179 May Jun 2017 B2
9795725 Joshi et al. Oct 2017 B2
9808561 Adie et al. Nov 2017 B2
9844473 Blott et al. Dec 2017 B2
9877872 Mumby et al. Jan 2018 B2
9962474 Greener May 2018 B2
10016309 Hartwell Jul 2018 B2
10046096 Askem et al. Aug 2018 B2
10130519 Mumby et al. Nov 2018 B2
10201644 Haggstrom et al. Feb 2019 B2
10610414 Hartwell et al. Apr 2020 B2
20010000795 Bolian, II et al. May 2001 A1
20010016985 Insley et al. Aug 2001 A1
20010018308 Quick et al. Aug 2001 A1
20010027302 Glaug et al. Oct 2001 A1
20010027305 Raidel et al. Oct 2001 A1
20010044610 Kim et al. Nov 2001 A1
20010053904 Abuto Dec 2001 A1
20020007167 Dan et al. Jan 2002 A1
20020007169 Graef et al. Jan 2002 A1
20020019614 Woon et al. Feb 2002 A1
20020026166 Graef et al. Feb 2002 A1
20020034914 De Leon et al. Mar 2002 A1
20020035352 Ronnberg et al. Mar 2002 A1
20020035354 Mirle et al. Mar 2002 A1
20020062113 Thomas et al. May 2002 A1
20020064639 Rearick et al. May 2002 A1
20020087136 Widlund Jul 2002 A1
20020090511 Smith et al. Jul 2002 A1
20020110672 Muratore-Pallatino et al. Aug 2002 A1
20020123728 Graef et al. Sep 2002 A1
20020133132 Copat et al. Sep 2002 A1
20020150678 Cramer et al. Oct 2002 A1
20020165509 Baer et al. Nov 2002 A1
20020176964 Koslow Nov 2002 A1
20020177831 Daley et al. Nov 2002 A1
20020180092 Abba et al. Dec 2002 A1
20020183704 Fields et al. Dec 2002 A1
20030045707 West et al. Mar 2003 A1
20030050617 Chen et al. Mar 2003 A1
20030070780 Chen et al. Apr 2003 A1
20030073967 Wahlstrom et al. Apr 2003 A1
20030088229 Baker et al. May 2003 A1
20030088231 Yoshimasa et al. May 2003 A1
20030093044 Wahlstrom et al. May 2003 A1
20030097101 Schmidt et al. May 2003 A1
20030097105 Chen et al. May 2003 A1
20030097113 Molee May 2003 A1
20030105442 Johnston et al. Jun 2003 A1
20030114816 Underhill et al. Jun 2003 A1
20030114818 Benecke et al. Jun 2003 A1
20030114821 Underhill et al. Jun 2003 A1
20030120249 Wulz et al. Jun 2003 A1
20030121588 Pargass et al. Jul 2003 A1
20030124311 Cree et al. Jul 2003 A1
20030125646 Whitlock Jul 2003 A1
20030134559 Delzer et al. Jul 2003 A1
20030135177 Baker Jul 2003 A1
20030150551 Baker Aug 2003 A1
20030157857 Cook et al. Aug 2003 A1
20030171729 Kaun et al. Sep 2003 A1
20030180341 Gooch et al. Sep 2003 A1
20030208175 Gross et al. Nov 2003 A1
20030212359 Butler Nov 2003 A1
20030225383 Glaug et al. Dec 2003 A1
20040019338 Litvay et al. Jan 2004 A1
20040019339 Ranganathan et al. Jan 2004 A1
20040019340 McBride Jan 2004 A1
20040019342 Nagasuna et al. Jan 2004 A1
20040024375 Litvay Feb 2004 A1
20040033750 Everett et al. Feb 2004 A1
20040054343 Barnett et al. Mar 2004 A1
20040054344 Roettger et al. Mar 2004 A1
20040057855 Gerlach et al. Mar 2004 A1
20040065420 Graef et al. Apr 2004 A1
20040078016 Baker Apr 2004 A1
20040087927 Suzuki May 2004 A1
20040111074 Eliasson Jun 2004 A1
20040127862 Bubb et al. Jul 2004 A1
20040177935 Hamed et al. Sep 2004 A1
20040181199 Moberg-Alehammar et al. Sep 2004 A1
20040204696 Chen Oct 2004 A1
20040230173 Barge et al. Nov 2004 A1
20040230184 Babusik et al. Nov 2004 A1
20040243042 Lipman Dec 2004 A1
20040243080 Baer Dec 2004 A1
20040243081 Suzuki et al. Dec 2004 A1
20040253894 Fell et al. Dec 2004 A1
20040254552 Mangold Dec 2004 A1
20050008825 Casey et al. Jan 2005 A1
20050013992 Azad et al. Jan 2005 A1
20050049566 Vukos et al. Mar 2005 A1
20050079361 Hamed et al. Apr 2005 A1
20050096616 Arora et al. May 2005 A1
20050112979 Sawyer et al. May 2005 A1
20050119631 Giloh et al. Jun 2005 A1
20050136773 Yahiaoui et al. Jun 2005 A1
20050165371 Giacometti Jul 2005 A1
20050215965 Schmidt et al. Sep 2005 A1
20050215967 Toro et al. Sep 2005 A1
20050222547 Beruda et al. Oct 2005 A1
20050228353 Thomas Oct 2005 A1
20050261649 Cohen Nov 2005 A1
20050267429 Cohen Dec 2005 A1
20060009744 Edrman et al. Jan 2006 A1
20060020250 Chester et al. Jan 2006 A1
20060058750 Di Girolamo et al. Mar 2006 A1
20060069366 Cole Mar 2006 A1
20060069367 Waksmundzki et al. Mar 2006 A1
20060069375 Waksmundzki et al. Mar 2006 A1
20060122548 Abrams Jun 2006 A1
20060122572 Suarez Jun 2006 A1
20060153904 Smith et al. Jul 2006 A1
20060161122 Erdman et al. Jul 2006 A1
20060178650 Hakannsson et al. Aug 2006 A1
20060184147 Hamed Aug 2006 A1
20060206047 Lampe et al. Sep 2006 A1
20060206073 Crane et al. Sep 2006 A1
20060206074 Bernal et al. Sep 2006 A1
20060282028 Howard et al. Dec 2006 A1
20070003604 Jones Jan 2007 A1
20070040454 Freudenberger et al. Feb 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070073254 Ponomarenko et al. Mar 2007 A1
20070100308 Miyairi May 2007 A1
20070167096 Scott Jul 2007 A1
20070167884 Mangrum et al. Jul 2007 A1
20070224903 Chakravarty et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070254550 Hamed et al. Nov 2007 A1
20070270070 Hamed Nov 2007 A1
20080004581 Babusik et al. Jan 2008 A1
20080015532 Waksmundzki Jan 2008 A1
20080031748 Ihle et al. Feb 2008 A1
20080082075 Morrell-Schwartz Apr 2008 A1
20080090050 Seyler et al. Apr 2008 A1
20080114317 Seyler May 2008 A1
20080119586 Byerly et al. May 2008 A1
20080132821 Propp et al. Jun 2008 A1
20080147024 Potts et al. Jun 2008 A1
20080243100 Wu et al. Oct 2008 A1
20080255533 Wu et al. Oct 2008 A1
20080306456 Riesinger Dec 2008 A1
20080312621 Hundorf et al. Dec 2008 A1
20080312622 Hundorf et al. Dec 2008 A1
20090062760 Wright et al. Mar 2009 A1
20090076472 Goldwasser et al. Mar 2009 A1
20090112175 Bissah et al. Apr 2009 A1
20090125004 Shen et al. May 2009 A1
20090157024 Song Jun 2009 A1
20090204087 Herfert et al. Aug 2009 A1
20090216168 Eckstein et al. Aug 2009 A1
20090234306 Vitaris Sep 2009 A1
20090299251 Buan Dec 2009 A1
20090299255 Kazala, Jr. et al. Dec 2009 A1
20090299306 Buan Dec 2009 A1
20100010461 Herfert et al. Jan 2010 A1
20100030171 Canada et al. Feb 2010 A1
20100036342 Carlucci et al. Feb 2010 A1
20100048072 Kauscheke et al. Feb 2010 A1
20100055158 Vitaris et al. Mar 2010 A1
20100069858 Olson Mar 2010 A1
20100106120 Holm Apr 2010 A1
20100121298 Seyler et al. May 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100168695 Robles et al. Jul 2010 A1
20100217177 Cali et al. Aug 2010 A1
20100256545 Aali et al. Oct 2010 A1
20100256584 Litvay Oct 2010 A1
20100256586 Bergstrom et al. Oct 2010 A1
20100259406 Caso et al. Oct 2010 A1
20100262091 Larsson Oct 2010 A1
20100305526 Robinson et al. Dec 2010 A1
20100318047 Ducker et al. Dec 2010 A1
20100318052 Ha et al. Dec 2010 A1
20100324516 Braga et al. Dec 2010 A1
20110004172 Eckstein et al. Jan 2011 A1
20110034892 Buan Feb 2011 A1
20110052664 Tennican et al. Mar 2011 A1
20110059329 Dobrawa et al. Mar 2011 A1
20110060303 Bissah et al. Mar 2011 A1
20110118683 Weston May 2011 A1
20110125119 Weismantel et al. May 2011 A1
20110137222 Masini Jun 2011 A1
20110152813 Ellingson Jun 2011 A1
20110178375 Forster Jul 2011 A1
20110183109 Seyler et al. Jul 2011 A1
20110184364 Biggs et al. Jul 2011 A1
20110184370 Seyler et al. Jul 2011 A1
20110208145 Zhang et al. Aug 2011 A1
20110213286 Riesinger Sep 2011 A1
20110218509 Dontas Sep 2011 A1
20110223413 Herfert et al. Sep 2011 A1
20110224631 Simmons Sep 2011 A1
20110238026 Zhang et al. Sep 2011 A1
20110245788 Canada Oct 2011 A1
20110247636 Pollack Oct 2011 A1
20110257572 Locke et al. Oct 2011 A1
20110268932 Catalan et al. Nov 2011 A1
20120004632 Zhang et al. Jan 2012 A1
20120041402 Greener Feb 2012 A1
20120045639 Whitmore et al. Feb 2012 A1
20120051945 Orndorff et al. Mar 2012 A1
20120053547 Schroeder et al. Mar 2012 A1
20120065664 Avitable et al. Mar 2012 A1
20120071848 Zhang et al. Mar 2012 A1
20120095380 Gergley et al. Apr 2012 A1
20120095426 Visscher et al. Apr 2012 A1
20120101465 Mcguire, Jr. Apr 2012 A1
20120123311 Weidemann-Hendrickson et al. May 2012 A1
20120136329 Carney May 2012 A1
20120143158 Yang et al. Jun 2012 A1
20120165765 Barta et al. Jun 2012 A1
20120172778 Rastegar et al. Jul 2012 A1
20120197229 Buan Aug 2012 A1
20120203145 Nilsson Aug 2012 A1
20120203189 Barta et al. Aug 2012 A1
20120220968 Confalone et al. Aug 2012 A1
20120238932 Atteia et al. Sep 2012 A1
20120302440 Theliander et al. Nov 2012 A1
20120308780 Rottger et al. Dec 2012 A1
20120310186 Moghe et al. Dec 2012 A1
20120310197 Thomas Dec 2012 A1
20120330253 Robinson et al. Dec 2012 A1
20130012902 Rovaniemi Jan 2013 A1
20130066285 Locke et al. Mar 2013 A1
20130066289 Song et al. Mar 2013 A1
20130090616 Neubauer Apr 2013 A1
20130116635 Fleischmann May 2013 A1
20130138054 Fleischmann May 2013 A1
20130144227 Locke et al. Jun 2013 A1
20130144230 Wu et al. Jun 2013 A1
20130150814 Buan Jun 2013 A1
20130165878 Heagle Jun 2013 A1
20130190705 Vess et al. Jul 2013 A1
20130274688 Weston Oct 2013 A1
20130296762 Toth Nov 2013 A1
20130302545 Schnelker et al. Nov 2013 A1
20130310781 Phillips et al. Nov 2013 A1
20130331822 Patel et al. Dec 2013 A1
20140024989 Ueda Jan 2014 A1
20140094730 Greener Apr 2014 A1
20140114268 Auguste et al. Apr 2014 A1
20140200533 Whyte et al. Jul 2014 A1
20140228791 Hartwell Aug 2014 A1
20140316359 Collinson et al. Oct 2014 A1
20150032035 Banwell et al. Jan 2015 A1
20150119831 Robinson et al. Apr 2015 A1
20150119832 Locke Apr 2015 A1
20150119833 Coulthard et al. Apr 2015 A1
20150159066 Hartwell et al. Jun 2015 A1
20150182677 Collinson et al. Jul 2015 A1
20150190286 Allen et al. Jul 2015 A1
20150216733 Allen et al. Aug 2015 A1
20150308994 Hammond et al. Oct 2015 A1
20150320602 Locke et al. Nov 2015 A1
20160000611 Niederauer et al. Jan 2016 A1
20160136339 Begin et al. May 2016 A1
20160144084 Collinson et al. May 2016 A1
20160298620 Cordoba et al. Oct 2016 A1
20160317357 Vitaris et al. Nov 2016 A1
20170007751 Hartwell et al. Jan 2017 A1
20170128642 Buan May 2017 A1
20170181896 Hartwell Jun 2017 A1
20170181897 Hartwell Jun 2017 A1
20170368239 Askem et al. Dec 2017 A1
20180133378 Askem et al. May 2018 A1
20180221211 Luckemeyer et al. Aug 2018 A1
20180235646 Locke et al. Aug 2018 A1
20180296397 Askem et al. Oct 2018 A1
20180318476 Askem et al. Nov 2018 A1
20190240385 Hartwell et al. Aug 2019 A1
20200121833 Askem et al. Apr 2020 A9
20200139023 Haggstrom et al. May 2020 A1
Foreign Referenced Citations (146)
Number Date Country
101744688 Jun 2010 CN
102038575 May 2011 CN
103405846 Nov 2013 CN
34 43 101 May 1986 DE
20 2004 017 052 Jul 2005 DE
0 257 916 Mar 1988 EP
0 340 018 Nov 1989 EP
0392640 Oct 1990 EP
0630629 Dec 1994 EP
0 549 781 Sep 1996 EP
0 748 894 Dec 1996 EP
0 599 871 Apr 1997 EP
0 875 224 Nov 1998 EP
0 941 726 Sep 1999 EP
1 013 290 Jun 2000 EP
1 048 278 Nov 2000 EP
1 066 809 Jan 2001 EP
1 139 951 Oct 2001 EP
1 312 328 May 2003 EP
1 452 156 Sep 2004 EP
1 476 217 Mar 2008 EP
1 955 887 Aug 2008 EP
2 161 011 Mar 2010 EP
2 263 627 Dec 2010 EP
2 366 721 Sep 2011 EP
2 021 046 Mar 2012 EP
2 462 908 Jun 2012 EP
2 529 767 Dec 2012 EP
2 544 642 Jan 2015 EP
2 648 668 Jan 2015 EP
1 163 907 Oct 1958 FR
1255395 Dec 1971 GB
2355228 Apr 2001 GB
2435422 Aug 2007 GB
2435423 Aug 2007 GB
2489947 Oct 2012 GB
2496310 May 2013 GB
2014-168573 Sep 2014 JP
101333344 Nov 2013 KR
WO 198300742 Mar 1983 WO
WO 199111161 Aug 1991 WO
WO 199111162 Aug 1991 WO
WO 199301778 Feb 1993 WO
WO 199301779 Feb 1993 WO
WO 199301780 Feb 1993 WO
WO 199301781 Feb 1993 WO
WO 199309745 May 1993 WO
WO 199311726 Jun 1993 WO
WO 1994023677 Oct 1994 WO
WO 199513042 May 1995 WO
WO 199513776 May 1995 WO
WO 199513779 May 1995 WO
WO 1995014451 Jun 1995 WO
WO 199516424 Jun 1995 WO
WO 1995029959 Nov 1995 WO
WO 1996005873 Feb 1996 WO
WO 199607783 Mar 1996 WO
WO 199711658 Apr 1997 WO
WO 199714384 Apr 1997 WO
WO 199820916 May 1998 WO
WO 199822279 May 1998 WO
WO 199904830 Feb 1999 WO
WO 199939671 Aug 1999 WO
WO 199945876 Sep 1999 WO
WO 199945878 Sep 1999 WO
WO 199956687 Nov 1999 WO
WO 200000016 Jan 2000 WO
WO 200000127 Jan 2000 WO
WO 200000129 Jan 2000 WO
WO 2000000130 Jan 2000 WO
WO 200000131 Jan 2000 WO
WO 2000040190 Jul 2000 WO
WO 200042957 Jul 2000 WO
WO 2000059438 Oct 2000 WO
WO 2001072251 Oct 2001 WO
WO 2001090465 Nov 2001 WO
WO 200217840 Mar 2002 WO
WO 2002024132 Mar 2002 WO
WO 2002026180 Apr 2002 WO
WO 2002076379 Oct 2002 WO
WO 2003073971 Sep 2003 WO
WO 2004043321 May 2004 WO
WO 2004077387 Sep 2004 WO
WO 2004098474 Nov 2004 WO
WO 2005025447 Mar 2005 WO
WO 2005123170 Dec 2005 WO
WO 2006052839 May 2006 WO
WO 2006105305 Oct 2006 WO
WO 2007035038 Mar 2007 WO
WO 2007040606 Apr 2007 WO
WO 2007077214 Jul 2007 WO
WO 2007077216 Jul 2007 WO
WO 2007116347 Oct 2007 WO
WO 2008039223 Apr 2008 WO
WO 2009066105 May 2009 WO
WO 2009124100 Oct 2009 WO
WO 2009146441 Dec 2009 WO
WO 2009152021 Dec 2009 WO
WO 2009158128 Dec 2009 WO
WO 2010032951 Mar 2010 WO
WO 2010082872 Jul 2010 WO
WO-2010075180 Jul 2010 WO
WO 2010089448 Aug 2010 WO
WO 2010139926 Dec 2010 WO
WO 2010142959 Dec 2010 WO
WO 2011023650 Mar 2011 WO
WO 2011058311 May 2011 WO
WO 2011113728 Sep 2011 WO
WO 2011128651 Oct 2011 WO
WO 2011135285 Nov 2011 WO
WO 2011135286 Nov 2011 WO
WO 2011135287 Nov 2011 WO
WO 2011144888 Nov 2011 WO
WO 2011152368 Dec 2011 WO
WO 2012035787 Mar 2012 WO
WO 2012041296 Apr 2012 WO
WO 2012074512 Jun 2012 WO
WO 2012106590 Aug 2012 WO
WO 2012131237 Oct 2012 WO
WO 2012140378 Oct 2012 WO
WO 2012143665 Oct 2012 WO
WO 2012150235 Nov 2012 WO
WO 2012168298 Dec 2012 WO
WO 2013010907 Jan 2013 WO
WO 2013014317 Jan 2013 WO
WO 2013029652 Mar 2013 WO
WO 2013060732 May 2013 WO
WO 2013064852 May 2013 WO
WO 2013083800 Jun 2013 WO
WO 2013090810 Jun 2013 WO
WO 2013136181 Sep 2013 WO
WO 2013149078 Oct 2013 WO
WO 2014008348 Jan 2014 WO
WO 2014014922 Jan 2014 WO
WO 2014016759 Jan 2014 WO
WO 2014020440 Feb 2014 WO
WO 2014020443 Feb 2014 WO
WO 2014108476 Jul 2014 WO
WO 2014113253 Jul 2014 WO
WO 2015022334 Feb 2015 WO
WO 2015022340 Feb 2015 WO
WO 2015031216 Mar 2015 WO
WO 2015110410 Jul 2015 WO
WO 2015130608 Sep 2015 WO
WO 2016018448 Feb 2016 WO
9605526 Feb 1997 ZA
Non-Patent Literature Citations (18)
Entry
U.S. Appl. No. 61/828,604, filed May 29, 2013, Collinson et al.
U.S. Appl. No. 61/829,187, filed May 30, 2013, Collinson et al.
U.S. Appl. No. 61/906,865, filed Nov. 20, 2013, Collinson et al.
U.S. Appl. No. 61/907,350, filed Nov. 21, 2013, Collinson et al.
“Technology Watch”, May 1989, in 1 page.
Hersle, K. et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies”, The Journal of Dermatologic Surgery and Oncology, vol. 8, Jan. 1982, in 4 pages.
International Search Report and Written Opinion, re PCT Application No. PCT/EP2015/063373, dated Sep. 2, 2015.
International Preliminary Report on Patentability, re PCT Application No. PCT/EP2015/063373, dated Dec. 29, 2016.
International Search Report and Written Opinion, re PCT Application No. PCT/GB2014/050786, dated Jun. 12, 2014.
International Search Report, re PCT Application No. PCT/EP2014/071510, dated Feb. 5, 2015.
International Preliminary Report for Patentability, re PCT Application No. PCT/EP2014/071510, dated Apr. 21, 2016.
International Search Report and Written Opinion, re PCT Application No. PCT/EP2014/071520, dated Feb. 5, 2015.
Kendall ULTEC Hydrocolloid Dressing (4″x4′), product ordering page, web page downloaded Jul. 13, 2014, in 1 page.
Advantec MFS, Inc., “Membrane Filters” (catalog), accessed Jan. 29, 2016 (publication date unknown, but believed to be copyright 2001-2011), in 17 pages. URL: http://www.advantecmfs.com/catalog/filt/membrane.pdf#page=11.
Protz, K., “Moderne Wundauflagen unterstutzen Heilungsprozess”, Wundversorgung: Indikation und Anwendung, Geriatrie Journal, Apr. 2005, pp. 3333-3339, with translation, in 17 pages.
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System”, spiral booklet, Mar. 2011, in 7 pages.
SNAP—BLUE Foam Dressing—color brochure (L22162 rev. 130429), Jun. 2013, in 2 pages.
SNAP—Product Overview—Wound Care System, as captured on Wayback Machine on Nov. 17, 2011.
Related Publications (1)
Number Date Country
20200297541 A1 Sep 2020 US
Provisional Applications (2)
Number Date Country
62013989 Jun 2014 US
62085774 Dec 2014 US
Continuations (1)
Number Date Country
Parent 15319743 US
Child 16841516 US